

# Genomic Essentials *for* Graduate Level Nurses

Edited by

**Diane C. Seibert, Ph.D, WHNP-BC, ANP-BC,  
FAANP, FAAN**

*Professor and Interim Associate Dean, Academic Affairs  
Daniel K. Inouye Graduate School of Nursing  
Uniformed Services University of the Health Sciences  
Bethesda, MD*

**Quannetta T. Edwards Ph.D, FNP-BC,  
WHNP-BC, AGN-BC, FAANP**

*Professor  
College of Graduate Nursing  
Western University of Health Sciences  
Pomona, CA*

**Ann H. Maradiegue, Ph.D, FNP-BC, FAANP**

*James Madison University  
Harrisonburg, VA*

**Susan T. Tinley, Ph.D, RN, CGC (RET)**

*Associate Professor Emerita  
Creighton University College of Nursing  
Omaha, NE*



DEStech Publications, Inc.

## **Genomic Essentials for Graduate Level Nurses**

DEStech Publications, Inc.  
439 North Duke Street  
Lancaster, Pennsylvania 17602 U.S.A.

Copyright © 2016 by DEStech Publications, Inc.  
All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Printed in the United States of America  
10 9 8 7 6 5 4 3 2 1

Main entry under title:  
Genomic Essentials for Graduate Level Nurses

A DEStech Publications book  
Bibliography: p.  
Includes index p. 433

Library of Congress Control Number: 2016932489  
ISBN: 978-1-60595-094-5

# Table of Contents

*Preface* xi

*List of Contributors* xiii

## **Chapter 1. Introduction to Basic Genetics and Genomics . . . . . 1**

SUSAN T. TINLEY

- 1.1. Introduction 1
- 1.2. DNA Structure and Replication 1
- 1.3. Numerical and Structural Cytogenetic Abnormalities 6
- 1.4. DNA and RNA Function 10
- 1.5. Mutations in the Genetic Code 15
- 1.6. Functional Effects of Mutations 18
- 1.7. Mendelian Patterns of Inheritance 19
- 1.8. Alterations to Mendelian Patterns 23
- 1.9. Non-Mendelian Patterns of Inheritance 25
- 1.10. Advances in Genomics and Pharmacogenomics 27
- 1.11. References 28

## **Chapter 2. A Primer: Risk Assessment, Data Collection, and Interpretation for Genomic Clinical Assessment. . . . . 31**

ANN H. MARADIEGUE and QUANNETTA T. EDWARDS

- 2.1. Definition of Terms Important for this Chapter 31
- 2.2. Introduction 33
- 2.3. Risk Assessment RAPID Approach—Step 1 Data Collection 35
- 2.4. RAPID Risk Assessment Approach—Identification of Red Flags 53
- 2.5. Pedigree Challenges—Confounding Factors in Inheritance Patterns 56
- 2.6. RAPID 2.3: Step 3—Determination of Risk Probability 57
- 2.7. RAPID 2.4: Step 4—Risk Assessment—Review Data and Communicate Risk to Client/Family 59
- 2.8. RAPID 2.5: Step 5—Risk Management 60
- 2.9. Nursing Implications of the Genomic Family History and Risk Assessment 60
- 2.10. References 62

## **Chapter 3. Testing and Counseling for Genetic and Genomic Conditions . . . . . 67**

SUSAN T. TINLEY

- 3.1. Introduction 67
- 3.2. Genetic Testing 67

3.3. Cytogenetics	68
3.4. Molecular or DNA Testing	69
3.5. Purpose of Testing	71
3.6. Genetic Counseling	73
3.7. Elements of Informed Consent for Genetic Testing	75
3.8. Support of Client Coping and Use of Genetic/Genomic Information	77
3.9. Genomics and Genetic Counseling	80
3.10. Conclusion	80
3.11. References	80
<b>Chapter 4. Ethical, Legal, and Social Implications in Genomic Advanced Practice Nursing</b>	<b>85</b>
KATHLEEN SPARBEL and MARTHA TURNER	
4.1. Introduction	85
4.2. Approaches in Bioethics	85
4.3. Ethical Standards and Ethical Competence in Nursing	88
4.4. Genetic and Genomic Competencies	88
4.5. Risk Assessment and Interpretation	90
4.6. Genetic Education, Counseling, Testing, and Results Interpretation	91
4.7. Clinical Management	93
4.8. Legal and Social Implications of Genetic and Genomic Information	94
4.9. Conclusion	96
4.10. References	96
<b>Chapter 5. Essentials of Pharmacogenomics</b>	<b>99</b>
JUNE ZHANG, YU LIU, JEFFERY FAN, BRADLEY T. ANDRESEN and YING HUANG	
5.1. Introduction to Pharmacogenomics	99
5.2. Pharmacokinetics (PK), Pharmacodynamics (PD), and Pharmacogenomics	103
5.3. Pharmacogenomics of Individual Drugs	103
5.4. Overall Summary and Future Opportunities for Nurses	114
5.5. References	116
<b>Chapter 6. Preconceptional and Prenatal Genomics</b>	<b>123</b>
MICHELLE MUNROE, DIANE C. SEIBERT and DANA KNUTZEN	
6.1. Introduction	123
6.2. Assessing Risk and the Family Health History (FHH)	123
6.3. Preconception Care	124
6.4. Epigenetics	125
6.5. Smoking	126
6.6. Seizure Disorder	126
6.7. Neural Tube Defect (NTD)	126
6.8. Genetic Conditions Affecting Fertility	127
6.9. Congenital Adrenal Hyperplasia	127
6.10. Fragile X Syndrome	128

6.11. Turner Syndrome	129
6.12. Klinefelter Syndrome	130
6.13. Cystic Fibrosis	130
6.14. Assisted Reproductive Technologies (ART)	131
6.15. Preimplantation Diagnostic Testing (PGD)	131
6.16. Maternal Genetic Conditions That May Adversely Affect Pregnancy Outcomes	131
6.17. Gestational Diabetes	131
6.18. Sickle Cell Disease	132
6.19. Cystic Fibrosis	132
6.20. Maternal Phenylketonuria (PKU)	133
6.21. Pregnancy Complications with a Genomic Etiology	133
6.22. References	136

## **Chapter 7. Newborn Screening ..... 141**

KAREN L. ZANNI

7.1. Introduction	141
7.2. History of Newborn Screening	141
7.3. New Technologies	143
7.4. Ethical, Legal, Social, and Practical Considerations	144
7.5. Implications for Educators, Researchers, and Administrators	146
7.6. References	147

## **Chapter 8. Genetic Considerations in Childhood ..... 149**

HEATHER L. JOHNSON, JOANNA SPAHIS and DALE H. LEA

8.1. Introduction	149
8.2. Assessment of Children with Atypical Features, Growth, or Development	149
8.3. Dysmorphology	150
8.4. Common Genetic Conditions	150
8.5. Growth	154
8.6. Short Stature	157
8.7. Tall Stature	161
8.8. Atypically Developing Children	164
8.9. The Six Core Elements of Health Care Transition	170
8.10. Using Transition Tools and Checklists	170
8.11. Summary	172
8.12. References	173

## **Chapter 9. Aging and Genomics: Perspectives for the Graduate Level Nurse ..... 177**

DEBRA L. SCHUTTE

9.1. Introduction	177
9.2. The Etiology of Aging	178
9.3. Aging, Genomics, and the Graduate Level Nurse	181

9.4. Summary	185
9.5. References	186
<b>Chapter 10. Respiratory Disorders</b>	<b>189</b>
RAN HE and JULIA EGGERT	
10.1. Introduction	189
10.2. Single-Gene Disorders	189
10.3. Complex Disorders	194
10.4. Case Study	203
10.5. References	205
<b>Chapter 11. Part 1—Genomics of Complex Cardiovascular Diseases</b>	<b>209</b>
JENNIFER R. DUNGAN, ALLISON A. VORDERSTRASSE, SARA M. JORDAN and ERICA A. JULIAN	
11.1. Introduction	209
11.2. Coronary Artery Disease (or Coronary Heart Disease)	210
11.3. Genetic Background	210
11.4. Genome-Wide Association Studies (GWAS) for CAD	210
11.5. The 9p21 Candidate Locus for CAD	211
11.6. Early-Onset CAD	213
11.7. Atherosclerosis/Arteriosclerosis	214
11.8. Dyslipidemias	214
11.9. Events: Myocardial Infarction and Survival	214
11.10. Gene Expression/Transcriptomics	215
11.11. Metabolomics	217
11.12. Pharmacogenomics Related to CAD Management	217
11.13. Essential Hypertension	218
11.14. Genetic Basis for Essential Hypertension	218
11.15. Early Candidate Genes in Hypertension	218
11.16. Genome Wide Associations for Essential Hypertension	220
11.17. Gene Expression/Transcriptomics	222
11.18. Metabolomics	222
11.19. Pharmacogenetics Related to Management of Essential Hypertension	223
11.20. Genomic Platforms and Their Clinical Utility	223
11.21. Nursing Implications Related to Genomic Testing Platforms	228
11.22. Conclusions	229
11.23. Future Directions	229
11.24. References	230
<b>Chapter 11. Part 2—Single Gene Cardiovascular Disorders</b>	<b>239</b>
SARAH RACE and MEGAN GROVE	
11.25. Introduction	239
11.26. Genetic Testing in Single Gene Cardiovascular Disorders	240
11.27. Role of Family History Taking in Inherited Single Gene Cardiovascular Disorders	241

11.28. Structural Inherited Single Gene Cardiovascular Disorders	242
11.29. Nonstructural Single Gene Cardiovascular Disorders	244
11.30. Future Genomic Technologies in Inherited Single-Gene Cardiovascular Care	249
11.31. Summary	250
11.32. References	250

## **Chapter 12. Genetics in Hematology . . . . . 255**

EDWARDA M. BUDA-OKREGLAK and DIANE C. SEIBERT

12.1. Introduction	255
12.2. Red Blood Cell Disorders	255
12.3. White Blood Cell (WBC) Disorders	264
12.4. Platelet Disorders	268
12.5. Coagulation Disorders	272
12.6. Inherited Bone Marrow Failure Syndromes (IBMFS)	277
12.7. Acquired Bone Marrow Failure Syndromes (ABMFS)	279
12.8. Hematologic Neoplasms	280
12.9. References	285

## **Chapter 13. Genetics and Genomics of Neurologic Disorders . . . . . 289**

SHEILA A. ALEXANDER

13.1. Introduction to the Nervous System	289
13.2. Single Gene Disorders of the Nervous System	289
13.3. Common Complex Disorders of the Central Nervous System	307
13.4. Conclusion	317
13.5. References	317

## **Chapter 14. Endocrine Disorders . . . . . 327**

CATHERINE LING and LUCIA NOVAK

14.1. Introduction	327
14.2. Inheritance Patterns	327
14.3. Assessing risk	333
14.4. Pharmacogenomics	339
14.5. Genetic Testing, Counseling, Ethical Implications	340
14.6. Acknowledgments	340
14.7. References	340

## **Chapter 15. Cancer Genomics: Current and Future Concepts to Define Health Care Practices and Personalized Care . . . . . 345**

QUANNETTA T. EDWARDS, ANN H. MARADIEGUE  
and KORY W. JASPERSON

15.1. Definition of Terms Associated with Cancer Genetics and Used in this Chapter	345
15.2. Introduction	346
15.3. Carcinogenesis—A Primer	348

15.4. Hereditary Cancer Syndromes	362
15.5. Hereditary Colon Cancer—Lynch Syndrome	378
15.6. Genomics of Cancer—New and Future Advances and Technologies	389
15.7. Utilization of the Rapid Approach: Selected Breast Cancer Case	394
15.8. References	397

**Chapter 16. Genomics in Nursing Education, Research, Leadership, and Practice. . . . . 409**  
 SUSAN T. TINLEY, QUANNETTA T. EDWARDS, ANN H. MARADIEGUE  
 and DIANE C. SEIBERT

16.1. Introduction	409
16.2. Nursing Education	409
16.3. Nursing Research	412
16.4. Nursing Leadership	413
16.5. Nursing Practice	415
16.6. References	415

**Chapter 17. Genomic Technologies. . . . . 417**  
 YVETTE P. CONLEY

17.1. Introduction	417
17.2. Next Generation Genome Sequencing	417
17.3. Gene Expression Profiling	418
17.4. Epigenomics	419
17.5. Conclusion	421
17.6. References	421

**Chapter 18. Genomics and Symptomatology. . . . . 423**  
 QUANNETTA T. EDWARDS, SUSAN T. TINLEY, DIANE C. SEIBERT  
 and ANN H. MARADIEGUE

18.1. Introduction	423
18.2. Genomics and Cancer-Related Fatigue	423
18.3. Genomics and Pain	425
18.4. Nursing Role and Symptomatology	428
18.5. References	428



## Preface

The purpose of this book is to improve the genomic competency of nurses prepared at the graduate level. The more informed graduate level nurses are about the rapidly evolving field of genomics, the more likely they are to apply it at the point of care, and the more prepared they will be to engage in conversations about how, when and where genomic technologies should be used in healthcare systems.

In 2009, a group of fifteen graduate nurses with genetics/genomics expertise from around the U.S. began a 2-year process to develop ‘The Essential Genetic/Genomic Competencies for Nurses with Graduate Degrees,’ an expanded set of genetic/genomic competencies tailored to meet the needs of nurses prepared at the graduate level. The competencies have two major domains, with each divided into seven major categories. The first domain, Professional Practice, includes (1) Risk Assessment & Interpretation; (2) Genetic Education, Counseling, Testing and Results Interpretation; and (3) Clinical Management. The second domain, Professional Responsibilities, comprises: (4) Ethical, Legal and Social Implications (ELSI); (5) Professional Role; (6) Leadership; and (7) Research.

The present volume evolved from and is based on constructs found in the graduate essentials mentioned above, and many of the chapters are authored by nurses who participated in developing the competencies. A number of chapters address the competencies in a clinical setting, while others, e.g., chapters 4 and 16, are focused exclusively on a single category within the competencies. The first five chapters provide the scientific underpinnings for genomic practice, which are Basic Genetic/Genomic Concepts, Risk Assessment, Genetic Testing and Counseling, ELSI and Pharmacogenomics. The next four chapters present genomic issues across the human lifespan: Preconceptional/Prenatal, Newborn Screening, Pediatrics and

Aging. The following six chapters review genetic and genomic contributions to disorders of selected body systems: Respiratory, Cardiology, Hematology, Neurology, Endocrine and Cancer. The next two chapters discuss issues unique to nursing, Genomics in Nursing Research, Practice, Administration & Education and Genomics and Symptomatology. The final chapter, Genomic Technologies, offers a glimpse of genomic advances that are being translated into clinical application. Because genomic science is evolving so quickly, new information was emerging daily as this book was being prepared. Each chapter therefore should be considered an orientation and introduction to a topic, in contrast to a comprehensive resource.

We would like to thank the talented inter-professional team of nurses, physicians, researchers, scientists, geneticists and genetic counselors who worked with us to turn an idea into reality. Inter-professional education and collaboration, endorsed by the Institute of Medicine and the American Association of Colleges of Nursing are essential to improve outcomes in today’s healthcare environment. This book’s collaborating authors represent a highly experienced group of health care professionals from a number of different specialties, including: advanced practice registered nurses (many who have received post-doctoral training at the National Institutes of Health or National Institute of Nursing Research), board-certified advanced genetics nurses, certified genetic counselors, physicians, nurse ethicists, molecular geneticists, nurse genetic scientists, nurse academicians, nursing leaders and administrators. Working in hospitals, specialty clinics, universities, laboratories and pharmacies throughout the world, these specialists devoted many hours to researching and writing chapters, sending references we may never have found otherwise, and furnishing valuable insight and support across the entire life of this writing

project. We wholeheartedly thank each and every contributor.

We hope readers find this book useful, informative and interesting. In creating it our ultimate goal has been to produce a resource that will improve healthcare outcomes for individuals, their families and communities by moving nursing

one step closer to the further goals of personalized healthcare and precision medicine.

DIANE C. SEIBERT  
QUANNETTA T. EDWARDS  
ANN H. MARADIEGUE  
SUSAN T. TINLEY

## List of Contributors

Sheila A. Alexander, Ph.D, RN

Bradley T. Andresen, Ph.D, FAHA

Edwarda M. Buda-Okreglak, MD, FACP

Yvette P. Conley, Ph.D

Jennifer R. Dungan, Ph.D, RN

Julia Eggert, Ph.D, GNP-BC, AOCN

Jeffery Fan, RN

Megan Grove, MS, LCGC

Ran He, Ph.D, AGN-BC

Ying Huang, Ph.D

Kory W. Jasperson, MS, CGC

Heather L. Johnson, DNP, FNP-BC, FAANP

Sara M. Jordan, BA, BSN, RN

Erica A. Julian, RN, BSN

Dana Knutzen, MS, CGC

Dale H. Lea, RN, MPH, CGC

Catherine Ling, Ph.D, FNP-BC, FAANP

Yu Liu, Ph.D, RN

Michelle Munroe, DNP, COL, AN, CNM

Lucia Novak, MSN, ANP-BC, BC-ADM

Sarah Race, RN, MSN, CNS

Debra L. Schutte, Ph.D, RN

Joanna Spahis, RN, CNS, APNG

Kathleen Sparbel, Ph.D, RN, FNP-BC

Martha Turner, Ph.D, RN-BC

Allison A. Vorderstrasse, DNSC, APRN

Karen L. Zanni, MSN, ARNP-BC, RN

June Zhang, Ph.D, RN



# Introduction to Basic Genetics and Genomics

SUSAN T. TINLEY, Ph.D, RN, CGC (RET)

## Objectives:

- Describe the difference between “genetics” and “genomics”.
- Explain the similarities and differences between mitosis and meiosis.
- Discuss normal and abnormal chromosome structure.
- Explain how DNA and RNA function in creation of gene products.
- Describe various alterations in the genetic code and their functional effects.
- Discuss details of each of the patterns of inheritance.

## 1.1. INTRODUCTION

Basic genetic/genomic concepts need to be understood to meet competencies outlined in the *Essential Genetic and Genomic Competencies for Nurses with Graduate Degrees* (Greco, Seibert & Tinley, 2012). This chapter provides a foundation for the remaining chapters in this book by offering a review of the basic principles of “genetics,” and introduces the concept of “genomics.” The traditional science of “genetics” is focused on exploring and explaining the impact of individual (or single) gene or chromosome changes, most of which are individually quite rare, on health. The broader term, “genomics,” considers the interactions between and within genes, regulatory sequences, and the environment. Genomics research is improving our understanding of genetic disorders, common complex health problems such as diabetes and heart disease, and disease prevention and treatment response. The basic science of “genetics” has evolved into “genomic healthcare.” For simplicity and continuity, the term genomics will be used throughout this book except when addressing specific genetic concepts or conditions. Because the genomics education of our readers may vary substantially, there are references at the end of the chapter to resources that can provide additional information. The reader is encouraged to refer back to these resources in the future, to stay current with the rapidly changing field of genomics and its impact on specific areas

of nursing practice, administration, research, and education.


## 1.2. DNA STRUCTURE AND REPLICATION

### 1.2.1. Structure of DNA and Chromosomes

Deoxyribonucleic acid (DNA) is the molecule that provides the genetic instructions for the development, growth, and ongoing functioning of any human being. There are two different cellular locations for DNA, in the nucleus (nuclear DNA [nDNA]) and in the mitochondria (mitochondrial DNA [mtDNA]). The nucleus is the location for the vast majority of human DNA; except in areas where both types of DNA are being discussed, it can be assumed that DNA is used to refer to DNA in the nucleus.

DNA is composed of two strands of polynucleotides. Each nucleotide is made up of a five carbon sugar, a phosphate, and a nitrogenous base. The appearance of DNA has been compared to a ladder which is coiled around core units of eight histones to provide support and stability to the structure.

The two sides of the ladder are composed of the alternating sugar and phosphate, and each sugar phosphate unit has a base attached. Hydrogen bonding between the bases holds the two strands together, forming the rungs of the ladder. One of the bases in a pair is larger, a purine, and the other is smaller, a pyrimidine. The purines



**FIGURE 1.1.** Chromosome. (Figure from the National Institutes of Health. National Human Genome Research Institute. Digital Media Database. Darryl Leja/NHGRI/NIH. Available at: <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85281>.)

are adenine and guanine (A and G) and the pyrimidines are cytosine and thymine (C and T). The pyrimidine thymine always pairs with the purine adenine (A and T) and the pyrimidine cytosine always pairs with the purine guanine (C and G). This consistent pairing is essential when the DNA replicates itself during cell division and during transcription and translation of the DNA code into proteins. A gene is a unit of the DNA that provides the code for a protein (Figure 1.1).

The nuclear DNA, which will be the primary focus of this chapter, is packaged into 23 pairs of chromosomes. Within each pair, 1 chromosome is maternally derived and the other is pater-

nally derived. Of the 23 pairs of chromosomes, 22 are the same for males and females and are called autosomes, numbered “1 to 22,” with 1 being largest and 22 the smallest. The 23rd pair of chromosomes determines the sex of the individual: XX for females and XY for males. The Y chromosome carries approximately 50 genes (National Library of Medicine [NLM] [U.S., 2014a), whereas the X chromosome, which is much larger, carries approximately 2,000 genes (NLM [U.S., 2014b).

The chromosome consists of two arms joined at a constriction point called the centromere. The shorter of the two arms is the p arm (for “pe-



FIGURE 1.2. Acrocentric, Metacentric, and Submetacentric Chromosomes. (Figure adapted from U.S. Department of Energy Genomic Science Program's Biological and Environmental Research Information System (BERIS). Individual chromosome illustrations available at: [https://public.ornl.gov/site/gallery/default.cfm?restsection=.](https://public.ornl.gov/site/gallery/default.cfm?restsection=))

tite”) and the longer arm is the q arm. Some of the pairs of chromosomes are the same size, but the centromeres are located in different positions on the chromosome. Chromosomes with centromeres located in the center (chromosomes 1, 3, 16, 19, and 20) are called metacentric; those with off-center centromeres (chromosomes 2, 4 to 12,

17, 18, X, and Y) are called submetacentric; and those with centromeres at the tip of the chromosome (chromosomes 13, 14, 15, 21, and 22) are acrocentric (Figure 1.2).

Another way of differentiating the chromosome pairs, in addition to their size and centromere placement, is by the distinctive patterns of




FIGURE 1.3. Chromosomes of the Human Genome. (Figure from National Human Genome Research Institute, Digital Media Database. Darryl Leja/NHGRI/NIH. Available at: <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85175>.)



light and dark bands (Figure 1.3). The tips of the chromosomes (similar to shoelace tips) are called telomeres (Figure 1.1), which act as a cap to prevent the chromosome from unraveling. Telomeres are made of many repeats of the sequence “TTAGGG,” and each time a cell divides, 20 to 30 of these TTAGGG repeats are lost. When all the telomere repeats are completely gone, the cell dies. Germ cells produce an enzyme called “telomerase,” which restores the telomeres to their original length so that at fertilization, there are sufficient repeats for the new individual’s lifetime (Read & Donnai, 2011).

### 1.2.2. The Cell Cycle

Each somatic cell goes through a cycle from its formation to its division into two daughter cells. There are four phases in each cell cycle: Gap1 (G1), S, Gap2 (G2), and M (Figure 1.4). During G1, the longest phase, individual chromosomes cannot be distinguished, because the DNA is unwound (extended) to allow easy access to the genetic code for protein production.

During the “S” phase, the DNA is reproduced in the process of replication (Figure 1.5) so that

each daughter cell receives an exact copy of the DNA from the original cell. During replication, the hydrogen bonds between the bases break so that the two strands of the DNA can separate. The bases of each strand attract new nucleotides with complementary bases, and hydrogen bonds form between the bases to hold the new strand to the old strand. Replication does not occur at the same time in all of the chromosomes or even within any given chromosome, but by the end of the S phase, all of the chromosomes are completely reproduced. Each of the original two DNA strands have been a template for a new complete molecule of DNA that is an exact copy of the original. The two identical copies of the chromosome are called sister chromatids, and they are held together at the centromere.

In the G2 phase, any replication errors that occurred during the S phase are detected and repaired. If the errors are too numerous or severe, programmed cell death (apoptosis) occurs. Malfunction in the process of apoptosis can lead to the development of cancer, which is discussed in greater depth in Chapter 15.

### 1.2.3. Mitosis

The M phase of the cell cycle is the phase in which the cell divides, forming 2 new cells. In somatic cells, this phase is called mitosis (Figure 1.6). During the first stage of mitosis (prophase), the chromosomes become tightly coiled and visible under a microscope. The nuclear membrane disappears and spindle fibers develop at the centrioles at either side of the cell, and the free end of the spindle fibers attach to the centromeres. During the second stage (metaphase), the chromosomes are highly condensed and most easily visualized under the microscope. During metaphase, the chromosomes are arranged along the equatorial plane of the cell, and the spindle fibers begin to contract, pulling the sister chromatids apart. During the third phase (anaphase), all the centromeres divide and the spindle fibers pull one sister chromatid to one side of the cell and the other to the opposite side. At the end of anaphase, there should be 92 chromosomes, with 46 on either side of the cell. During the next phase (telophase), a nuclear membrane develops around each group of 46 chromosomes, which are beginning to extend into indistinguishable




FIGURE 1.4. Cell Cycle. (Figure from National Human Genome Research Institute (NHGRI) Digital Media Database. Darryl Leja/NHGRI/NIH. Available at <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85276>.)






FIGURE 1.5. DNA Replication Prior to Cell Division. (Figure from Human Genome Program, U.S. Department of Energy, *Genomics and Its Impact on Science and Society: A 2008 Primer*, 2008. [Original version 1992, revised 2001 and 2008.] Available at: <https://public.ornl.gov/site/gallery/detail.cfm?id=393&topic=&citation=&general=DNA%20replication&restsection=all>.)

structures again. The division of the cytoplasm (cytokinesis) follows, forming two daughter cells which are identical to the original cell. These two daughter cells then enter interphase, which corresponds to G1, S, and G2 of the cell cycle.

#### 1.2.4. Meiosis

A different series of cell division steps occurs during meiosis, ultimately reducing the number of chromosomes in germ cells (sperm and ova) from 23 pairs (46 individual chromosomes) to 23 single chromosomes (Figure 1.7). To accomplish this, two cell divisions are required. As in mitosis, during meiosis, DNA replicates during prophase I, which occurs prior to the first meiotic division. In meiosis, prophase I is divided into five periods:

**Leptotene:** DNA becomes condensed, but the two chromatids are so tightly associated, they cannot be distinguished.

**Zygotene:** Chromosomes pair up (e.g., maternal chromosome 12 pairs up with paternal chromosome 12) and are held tightly together by the synaptonal complex.

**Pachytene:** Chromosomes condense even further and some genetic material from one chromosome trades places with genetic material of the other chromosome, creating four unique chromatids. This exchange is called crossing over or recombination.

**Diplotene:** The synaptonal complex disappears and the chromosomes in each pair start to separate. The two chromatids of each chromosome are still held together at the centromere.

**Diakinesis:** The chromosomes reach maximum condensation.

After prophase, the division steps proceed as in mitosis: the nuclear membrane dissolves, and the chromosome pairs align along the cells equatorial plane (metaphase I). Each pair then splits, and the individual chromosomes assort


randomly, with some paternally derived chromosomes going to one pole and others to the other side, and similarly with the maternally derived chromosomes (anaphase I). Because of random assortment of maternally and paternally derived chromosomes, there are  $2^{23}$  or  $> 8$  million possible chromosomal combinations. This tremendous potential for diversity is further increased by the crossing over that occurs during the pachytene period of prophase I (Clancy, 2008). The chromosomes group at either pole during telophase I and then the cell divides. The cell enters into a short interphase prior to beginning meiosis II.

During prophase of meiosis II, the nuclear membrane disappears and the spindle apparatus forms. In metaphase II, the chromosomes line up in the center of the cell, and in anaphase II, the

centromeres of the chromosomes separate as the spindle fibers pull the sister chromatids apart toward opposite poles. In telophase II, the nuclear membrane reforms and cytokinesis occurs so that there are now four cells, each having 23 chromosomes with a single chromatid. At the time of fertilization, the nuclei of the sperm and ovum join into one nucleus with 23 pairs of chromosomes, a unique combination of genetic information from mother and father.

### 1.3. NUMERICAL AND STRUCTURAL CYTOGENETIC ABNORMALITIES

Cytogenetics is the field that focuses on the examination of chromosomes for correct number and structure. A basic understanding of chro-



**FIGURE 1.6.** Mitosis. (Figure from National Institutes of Health, National Human Genome Research Institute. Digital Media Database. Darryl Leja/NHGRI/NIH. Available at: <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85204>.)




FIGURE 1.7. Meiosis. (Figure from National Institutes of Health. National Human Genome Research Institute. Digital Media Database. Darryl Leja/NHGRI/NIH. Available from; <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85196>.)

mosomal abnormalities is particularly important when caring for prenatal and pediatric populations and in oncology settings, because chromosomal abnormalities occur during reproduction and may arise in malignant cells, particularly those found in leukemia, lymphoma, and some solid tumors.

### 1.3.1. Nondisjunction

Meiosis usually produces germ cells with 23

chromosomes ready for fertilization with another germ cell with its own 23 chromosomes. Occasionally, however, a nondisjunction error occurs and chromosomes or chromatids fail to separate. Nondisjunction errors can occur either during the first or second meiotic division. If the nondisjunction occurs in the first meiotic division, one daughter cell receives an extra chromosome and the other is missing one, and when these cells go through the second meiotic division, the error is passed on to their respective daughter cells.

If nondisjunction occurs during the second division, the chromatids of one chromosome fail to separate, and two copies go to one cell and none to the other.

If a germ cell with 24 chromosomes is fertilized, it will contain three copies of one chromosome (trisomy). Conceptuses with Trisomy 13, 18, and 21 may survive to birth, whereas trisomies of other autosomes are lethal. Chromosome 13 has approximately 300 to 400 genes that code for proteins (NLM, 2014c). chromosome 18 has approximately 200 to 300 genes (NLM, 2014d), and chromosome 21 has approximately 200 to 300 genes (NLM, 2014e), fewer than any of the other autosomes. If a germ cell with 22 chromosomes is fertilized (monosomy), the embryo rarely survives because too little genetic information is usually lethal. The one monosomy that is compatible with survival is Monosomy X (Turner syndrome [TS]), although it is estimated that up to 99% of Monosomy X conceptuses miscarry in the first or second tri-

mester. It is theorized that those that survive to term have a mosaicism (Wolff, Van Dyke, & Powell, 2010).

### 1.3.2. Genetic Mosaicism

Genetic mosaicism is the result of a chromosomal nondisjunction or DNA mutation that develops during a very early mitotic division after fertilization. The individual develops with both normal and abnormal cell lines. Individuals affected with a chromosomal mosaicism usually are more mildly affected (milder phenotype) than someone with a meiotic nondisjunction, because at least some of their cells have a normal chromosomal complement. Females with TS (45 X) often have a mosaic form of the disorder.

### 1.3.3. Translocations

Some chromosomal abnormalities are due to translocations of which there are two major




FIGURE 1.8. Reciprocal translocation. (Figure from National Institutes of Health. National Human Genome Research Institute. Digital Media Database. Daryl Leja/ NHGRI/NIH. Available at <http://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85253>.)






FIGURE 1.9. Chromosomal Inversion. (Figure from United States National Library of Medicine. Genetics Home Reference. Available at <http://ghr.nlm.nih.gov/handbook/illustrations/inversion>.)

types, Robertsonian and reciprocal. Robertsonian translocations develop when the centromere of one acrocentric chromosome fuses with the centromere of another acrocentric chromosome. The two most common types are Robertsonian and reciprocal translocations.

Robertsonian translocations should be considered when a couple has more than one child with Down syndrome (DS). Although DS is most frequently due to a nondisjunctional error, about 5%

of DS is the result of an unbalanced Robertsonian translocation. In an unbalanced Robertsonian translocation of chromosomes 14 and 21, the offspring inherits the translocated chromosome as well as two normal 21s and one normal 14. The embryo has a normal number of chromosomes (46), but because of the fused 21 and 14, it inherits three copies of chromosome 21 and manifests the typical DS phenotype.

Standard nomenclature for translocation DS in

## Genomics and Symptomatology

QUANNETTA T. EDWARDS, Ph.D, FNP-BC, WHNP-BC, AGN-BC, FAANP  
SUSAN T. TINLEY, Ph.D, RN, CGC (RET)  
DIANE C. SEIBERT, Ph.D, ARNP, FAANP, FAAN  
ANN H. MARADIEGUE, Ph.D, FNP-BC, FAANP

### Objectives:

- Discuss the impact of genomics on cancer related fatigue.
- Discuss the genes associated with pain.
- Explain the role of nursing regarding genomics and symptomatology.

### 18.1. INTRODUCTION

An individual's genome impacts the trajectory of their health and illness throughout life. Thus far, the focus of this book has been on the impact of genomics as it relates to an individual's response to drugs, their risk for developing diseases based on their family history, or as a result of shared genetic and environmental factors. Beyond health, illness, and the effectiveness of drugs, genomics also influences how an individual experiences a particular disorder—or the *symptomatology* of that condition. Research examining the genetics of common symptoms offers the promise of reducing adverse symptoms and improving quality of life, which is particularly important, because symptom management is a key function for nursing.

In this chapter, brief overviews of two common symptoms are discussed. These symptoms are *cancer-related fatigue* and *pain*, as each of these symptoms have been shown to be influenced by genomic discoveries. The role of genomic variants (i.e., single nucleotide polymorphisms [SNPs]) influencing the onset, duration, or severity of symptoms, as well as how they influence therapeutic responses in preventing, alleviating, or eliminating patient's symptoms, will be discussed. Where applicable, other influences that may potentiate the effects of genomic variants in symptom manifestation and treatment

will be described. Genomic advances in symptom management will help ensure that the right person receives the right therapy (personalized or precision health care), will reduce adverse effects, and will improve both quality of life and overall health outcomes.

### 18.2. GENOMICS AND CANCER-RELATED FATIGUE

Fatigue is a symptom manifested in patients that is associated with a wide range of diseases and syndromes that often affect individual's physical, social, and mental functioning (Landmark-Hoyvik *et al.*, 2010). It is also one of the most commonly reported symptoms in individuals diagnosed with cancer, often resulting in increased stress and anxiety and other health-related quality of life issues including, but not limited to, impaired physical performance, inactivity, helplessness, sleep disturbances, lack of appetite, and/or depression (Escalante, Kallen, Valdres, Morrow, & Manzullo, 2010; Horneber, Fischer, Dimeo, Ruffer, & Weis, 2012; Saligan & Kim, 2012). *Cancer-related fatigue* (CRF) is defined as a “distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning” (National Comprehensive Cancer Network (NCCN), 2015m p. MS-3). The symptoms of

CRF can occur during and after treatment of the cancer and are often attributed to treatment regimens, such as cytotoxic chemotherapy, radiation therapy, or other biological treatments. However, CRF can vary, occurring any time in the course of disease, and may be self-limiting or persisting for many years even after treatment (Bower *et al.*, 2006; Horneber *et al.*, 2012). For example, in one longitudinal study of breast cancer survivors, approximately 34% of the participants reported fatigue 5 to 10 years after diagnosis (Bower *et al.*, 2006). Similar effects regarding fatigue persistence after diagnosis and treatment have been reported (Husson *et al.*, 2013; Hwang *et al.*, 2014).

Fatigue among patients with cancer can be associated with multifactorial etiologies and manifest in a myriad of clinical features (Horneber *et al.*, 2012; NCCN, 2015). Contributing factors to fatigue include pain, emotional distress, sleep disturbances, and co-morbidities such as anemia; poor nutrition; physical inactivity; medication side effects; alcohol and/or substance abuse; therapeutic management with cytotoxic, biologic, or radiation therapy; or other medical conditions (National Cancer Institute, 2013; NCCN, 2015). However, the diagnostic criteria for CRF include fatigue, distress, or impairment due to fatigue, etiology related to cancer or cancer treatment, and the exclusion of underlying psychiatric or medical disorders. CRF is common, with studies revealing varied prevalence estimates ranging from 25% to 99% of patients with cancer experiencing this symptom, depending on the population and type of assessment (Bower, 2007). Most common clinical manifestations of CRF are focused on fatigue, lack of energy, exhaustion, or impaired physical function that can affect physical or psychosocial well-being of the individual (Horneber *et al.*, 2012).

The exact biological mechanisms of CRF are unknown; however, some proposed mechanisms associated with the symptom include 5-HT<sub>3</sub> neurotransmitter deregulation, disturbances in hypothalamic regulation, dysregulation in circadian rhythm, skeletal muscle wasting, pro-inflammatory cytokines, or dysregulation of inflammatory cytokines (Barsevick *et al.*, 2013; Bower & Lamkin, 2013; Horneber *et al.*, 2012; NCCN, 2015; Ryan *et al.*, 2007). Genomic factors associated with inflammation have been linked to CRF prior

to, during, and after treatment, particularly in the pro-inflammatory cytokine network (Bower & Lamkin, 2013). Molecular-genetics, particularly gene polymorphisms, have shown to possibly play an important role in the mechanism of CRF. One example is that of proinflammatory cytokine SNP that influences interleukin (IL) and/or tumor necrosis factor (TNF) genes (i.e., *IL1B*; *IL-6*; *TNF $\alpha$* ) and is associated with CRF both during and after treatment (Aouizerat *et al.*, 2009; Bower, 2007; Bower & Lamkin, 2013; Miaskowski *et al.*, 2010). Alteration in pro-inflammatory cytokine production of *IL6* and other inflammatory markers has been linked with persistent fatigue among breast cancer survivors (Bower *et al.*, 2006; Collado-Hidalgo, Bower, Ganz, Cole, & Irwin, 2006). Persistent CRF among patients with breast cancer has also been found to be associated with increased activity of pro-inflammatory transcription factors NF- $\kappa$ B activity and decreased expression of glucocorticoid receptor anti-inflammatory transcription factors (Bower, Ganz, Irwin, Arevalo, & Cole, 2011). The association with CRF and cytokines, the proteins that mediate cell-to-cell communication, may be due to dysregulation of cytokines often attributed to cancer and cancer treatments that increase plasma levels of many cytokines, particularly the *TNF- $\alpha$*  and certain *IL* genes (Ahlberg, Ekmanb, Gaston-Johansson, & Mock, 2003; Ryan *et al.*, 2007). Cytokines are important for the development and functioning of the immune response, and aberrant expression from genetic polymorphisms have been associated with overall disease and functionality (Smith & Humphries, 2009). Pro-inflammatory cytokines, particularly *IL-1B*, *IL-6* and *TNF- $\alpha$* , are thought to induce symptoms of fatigue via signaling of the central nervous system through varied somnogenic influence (Weschenfelder, Sander, Kluge, Kirkby, & Himmerich, 2012).

The nuclear factor NF- $\kappa$ B, pro-inflammatory transcription factor, for example, is activated by the cancerous tumor microenvironment (Aggarwal, 2004) and, thus, pretreatment CRF may be due to tumorigenesis (Bower & Lamkin, 2013). Fatigue often occurs also during treatment, particularly due to chemotherapy or radiation therapy; this effect has been associated with elevations in inflammatory markers secondary to the therapeutic intervention. For example, in one

study, changes in inflammatory markers, including C-reactive protein and IL1 receptor antagonist, were found to be associated with fatigue symptoms among certain individuals with breast and ovarian cancer (Bower *et al.*, 2009). CRF has been found to occur years after completion of therapy in breast cancer survivors and alterations in proinflammatory markers also have been found among these individuals (Collado-Hidalgo *et al.*, 2006; Orre *et al.*, 2009).

Besides pro-inflammatory genes, other genomic factors are currently being studied to determine their impact on fatigue among cancer patients. For example, the relationship between dysfunction in certain mitochondrial genes has been found among prostate cancer patients receiving external beam radiation (Hsiao, Wang, Kaushal, & Saligan, 2013). Advances in genomic technologies will certainly change the face of understanding the molecular impact of genetics and CRF that will enhance predicting and managing the symptoms and improving outcomes.

### 18.2.1. Future Implications—Cancer Related Fatigue and Genomics

Although many studies have shown an association with varied inflammatory markers and CRF among patients with cancer, causality has not been established and gaps in knowledge continue, warranting further research in this area (Saligan & Kim, 2012). Specifically, problems exist regarding measurement of CRF, exact understanding of the underlying biology of the symptom, and clinical trials targeted towards CRF (Barsevick *et al.*, 2013). However, future links between CRF and inflammatory markers may be a means to provide personalized/precision medicine as a prognostic biomarker for fatigue among cancer patients or genetic predictors of fatigue for therapeutic management (Collado-Hidalgo *et al.*, 2006; Jim *et al.*, 2012), as well as future development of effective treatments such as cytokine antagonists targeting CRF (Bower & Lamkin, 2013). Further, because fatigue is a complex symptom with phenotypic heterogeneity, the inclusion of biobehavioral research of fatigue may provide clarity and contribute to the understanding of CRF and to future development of genetic/genomic interventions (Lyon, McCain, Pickler, Munro, & Elswick, 2011). The international and

interdisciplinary *GeneQoL Consortium* is one means to improve patient outcomes regarding issues that impact quality of life, including that of fatigue (GeneQoL Consortium, 2015; Sprangers *et al.*, 2009). This consortium was established to investigate genetic disposition of patient-reported quality-of-life outcomes in order to gain insight on the impact of disease and treatment on patient outcomes (GeneQoL Consortium, 2015). Clinical implications of the consortium are based on obtaining genetic knowledge, including understanding biological pathways that may impact quality of life (GeneQoL Consortium, 2015), and incorporating understanding of the biological and genetic mechanisms of CRF (Barsevick, Frost, Zwinderman, Hall, & Halyard, 2010).

## 18.3. GENOMICS AND PAIN

Pain is universal and has been described since antiquity, and yet the biochemical pathways and pathophysiologic underpinnings of pain are only now beginning to be unraveled. An excellent review of the history of pain and pain management can be found in the article by Meldrum (2003). Despite the lack of understanding and effective therapies to manage pain, helping patients and families cope with the manifestations of pain has been a central feature and core mission area for nurses since at least the 19th century, when Florence Nightingale discussed pain management in “Notes on Nursing” (Nightingale, 1860). Since then, many resources have been developed to improve nursing competency in pain management, including a pain management nursing certification awarded by the American Nurses Credentialing Center; establishment of the American Society for Pain Management Nursing (ASPMN) in 1991, which publishes a journal dedicated entirely to nursing management of pain; and nursing competencies focused on pain management ([http://mbon.maryland.gov/Documents/pain\\_management.pdf](http://mbon.maryland.gov/Documents/pain_management.pdf)).

Over 100 million Americans suffer from pain every year (Institute of Medicine ([U.S.] Committee on Advancing Pain Research, 2011), and a recent study estimates that chronic pain is more expensive than cancer, heart disease, and diabetes, costing up to \$635 billion a year (i.e., up to \$300 billion in direct costs and \$334 billion



in lost productivity) (Gaskin & Richard, 2012). Pain, a very important signaling mechanism in animals, plays a significant role in survival, because it forces the animal to protect an injury until it heals. Pain becomes chronic when the noxious stimuli persists after healing is complete, evolving into pain without a purpose. The *experience* of pain is highly variable; some people who experience acute pain from a noxious agent will develop chronic pain whereas others, exposed to the same causative agent, will not (Mogil, 2012). The *perception* of pain is highly individualized and subjective as well, as indicated by pain rating scores used in research and clinical settings. Finally, there is marked individualized variability in *response to analgesics*, with some people responding to very small doses and others requiring much larger doses to feel an effect (Aubrun, Langeron, Quesnel, Coriat, & Riou, 2003). All of this variability raises questions about the possibility that genetic factors could influence the experience of pain. More than 350 candidate genes have been associated with variability in pain sensitivity, and twin studies have clarified the heritability of pain in several specific conditions; however, to date, there are still many unanswered questions related to the basic genetic underpinnings of pain (Smith & Muralidharan, 2012).

Several classification systems have been developed to guide pain assessment and management. Some of the most common categorization systems include stratifying pain as acute or chronic, based on the length of time it has been present, or by intensity (mild to moderate, or severe). Numeric pain scales were developed to attempt to capture pain intensity. Physiologic changes (nociceptive, neuropathic, and inflammatory) and manifestations based on the affected tissue types (skin, muscles, viscera, joints, tendons, and bones) have also been used to categorize pain. Some diseases have classic pain characteristics; therefore, pain has been clustered by syndrome (cancer, fibromyalgia, migraine, etc.) (University of Wisconsin, 2014). This chapter reviews just a few of the areas being explored in the genomics of pain.

A few rare single gene disorders are associated with alterations in pain sensation, such as paroxysmal pain or a complete inability to feel pain. Although at first glance the genes appear to involve seemingly unrelated functional pro-

tein classes, on closer inspection, almost all the pathways involve the *SCN9A* gene in one way or another (Mogil, 2012). *SCN9A* encodes for the alpha subunit of the NaV1.7 sodium channel, expressed primarily in peripheral sensory nerves that transmit pain, touch, and smell signals to the central nervous system (Mogil, 2012). The role that *SCN9A* plays in more common pain responses is less clear (Young, Lariviere, & Belfer, 2012). Some studies have shown that variations in *SCN9A* alter pain responses (e.g., individuals with a G allele on *SCN9A* report lower pain scores compared with individuals having the less common A allele); other studies have been unable to consistently replicate those findings (Starkweather & Pair, 2013).

Genome wide association studies (GWAS) are changing the landscape of genomic research. GWAS tools such as computerized databases containing the reference human genome sequence, a map of human genetic variation, and new analytic technologies that can cheaply, rapidly, and accurately analyze whole-genome are making it possible to locate the genes associated with common diseases, such as asthma, diabetes, and heart disease. Once a new gene has been located, new strategies to detect, prevent, and/or treat a particular disorder can be developed.

Despite the rapid advances made in fields such as cardiology, oncology and hematology using GWAS, research into the genes associated with pain has lagged for several reasons. Reasons include the subjective nature of pain, relatively low funding levels, and associated lack of interest from researchers (Mogil, 2012). More recently, however, more research has been done to examine the genetic underpinnings of pain associated with diseases such as migraine headaches, osteoarthritis, endometriosis, Crohn's disease, and temporomandibular disorder (TMD) (Young *et al.*, 2012). Some of the genes found in these studies include a mutation in *ZNF429* and a gene upstream of the *RHBDF2* gene, whose function is currently unknown. Although no polymorphisms have been found in any of the known opioid receptor genes, ethnic differences appear to play an important role, because the strongest effect in one study was country of origin (Mogil, 2012). Despite the progress that has recently been made in understanding the genes associated with pain response, significant hurdles remain,

such as technology and data analysis limitations, explaining phenotypic heterogeneity, and the costs associated with conducting GWAS, which typically involve genotyping large numbers of people (Young *et al.*, 2012).

### 18.3.1. Epigenetics and Pain

As scientific understanding of epigenetic processes has increased over the past decade, there has been a concurrent surge of research exploring epigenetic mechanisms involved in regulating the nervous system, particularly the epigenetic processes associated with memory and synaptic plasticity (Denk & McMahon, 2012). Recent studies have found that epigenetic control is particularly important in three distinct areas: peripheral inflammation, pain processing, and plasticity.

When the body is exposed to a physical, chemical, or biologic insult, an inflammatory response develops rapidly to remove or destroy the injurious material, setting the stage for tissue repair and healing. Inflammation is commonly associated with pain, redness, heat, and swelling, which have been shown to increase healing, either because the injured person protects that area or because inflammatory cells, such as macrophages, produce high levels of insulin-like growth factor-1 (IGF-1), which increases the rate of healing and muscle regeneration (Lu *et al.*, 2011). The inflammatory response is highly complex, involving genes involved in a number of different processes, such as antimicrobial defense, immune response, tissue repair, and remodeling. Epigenetic changes in genes regulating macrophage function may play a particularly important role in inflammatory response, because they help macrophages change in response to different infectious organisms (Bayarsaihan, 2011). Epigenetic changes in T cells and monocytes, transcription factors found in several protein families (NF- $\kappa$ B, FOXP3, IRF, STAT), RE1-silencing transcription factors (REST), and histones (i.e., histone H4 hyperacetylation) have all been shown to regulate inflammatory response (Bayarsaihan, 2011; Selvi, Mohankrishna, Ostwal, & Kundu, 2010).

Inflammation persisting beyond the normal healing period is considered “chronic inflammation” characterized by chronic infiltration of

mononuclear immune cells and low antioxidant and high free radicals levels, creating an environment in which tissue healing is occurring at the same time tissue is being damaged, become a self-perpetuating cycle of injury, repair and usually, pain (Khansari, Shakiba, & Mahmoudi, 2009). Identifying the epigenetic mechanisms associated with the development of chronic pain may open the door to much needed advances in pain management (Denk & McMahon, 2012; Mogil, 2012). Epigenetic regulation of tissues in the nervous system is of particular interest, because these are the cells that generate and transmit pain signals, but also because the regeneration rate of individual neurons in the nervous system is very slow. The same neuron is likely to survive for decades, and because DNA is very resistant to change, epigenetic adjustments that occur over the life of the cell may be critical as they continually adapt to environmental stressors (Seo *et al.*, 2013). A neuron’s use of epigenetics to adapt to the environment is particularly important because such changes are reversible; therefore, if pain develops because of an epigenetic change, a drug that chemically “resets” the neuron to its normal state might be a powerful therapeutic tool (Seo *et al.*, 2013). Although there is evidence from animal studies to demonstrate that it is possible to modify epigenetic mechanisms with drugs (Geranton, 2012), more research needs to be done before human studies can begin to ensure that the drugs do not alter epigenetic mechanisms in other tissues (Crow, Denk, & McMahon, 2013).

Reinforcing the idea that epigenetics plays an important role in the development and perception of pain, data from genomic studies examining pain response is often contradictory. For example, *ORPM1*, a common m-opioid receptor variant, has been shown to increase bendorphin binding and activation of g-proteins in some studies, but this effect is not found in all studies on a consistent basis. Similarly, in some studies, individuals with *COMT* variations were found to have greater sensitivity to pain, but the same association has not been seen in other studies (Bond *et al.*, 1998; Kim *et al.*, 2004; Zubieta *et al.*, 2003). These inconsistencies suggest that factors, such as epigenetics, may play an important role in pain phenotypes (Seo *et al.*, 2013)

Opioids are used to treat pain on a routine ba-

sis, and many opioids are now approved for use, each of which has different efficacy and adverse response profiles based on the individual. If an individual has a poor response to one opioid, another is usually tried in a trial and error fashion until the most effective drug is found. Because this random approach exposes individuals to adverse effects and decreases quality of life, as the search for an effective analgesic agent continues, there has been considerable interest in finding the genetic factors that explain the variability in response to opioids (Branford, Droney, & Ross, 2012).

Several studies have found an association between the *A118G* SNP in *OPRM1* and opioid dosing (Chou *et al.*, 2006a; Chou *et al.*, 2006b; Reyes-Gibby *et al.*, 2007), but similar to the issues with *OPRM1* mentioned above, a meta-analysis of genetic association studies concluded that the *A118G* SNP is inconsistently associated with pain-related phenotypes (Walter & Lotsch, 2009). It is becoming clear that the genes associated with pain relief are not the same genes that influence the development of adverse effects, highlighting the need to carefully choose and define the phenotype being studied. It is also very likely that interactions among multiple genetic and environmental factors are playing important roles in the phenotype (Branford *et al.*, 2012).

Acute pain transforms into chronic pain in a complex series of discrete pathophysiologic and histopathologic steps involving more than 2000 gene changes in over 400 candidate genes. Broadly, the process involves neurons that abandon the normal “modulated” response to pain (reversible activation of intracellular signal-transduction cascades) and adopt a more persistent “modified” response involving relatively permanent changes to neuron activation (Voscopoulos & Lema, 2010). A growing body of evidence suggests that nociceptor modifications can occur in response to psychological triggers, further complicating research efforts (Diatchenko, Fillingim, Smith, & Maixner, 2013).

Understanding the genomics of individual variability in pain sensitivity, analgesic response, adverse reactions, and triggers that transform acute to chronic pain is still in its infancy. Once the genomic roadmap has been created, the highly complex interactions between the environment and the human genes that regulate the pain re-

sponse can then be explored, leading to a more effective and safe personalized approach to pain management.

## 18.4. NURSING ROLE AND SYMPTOMATOLOGY

Symptom management applies to nurses prepared at every level and practicing in virtually every setting—from nurses providing direct care to patients in inpatient and outpatient settings to conducting genomic research and to nursing faculty and nurses leading the largest health care systems. Nurses working at the point of care should be familiar with the emerging genetic information that helps support decisions that can improve the care of an individual patient, the goal of precision and personalized care. Nurses in faculty roles are responsible for ensuring that students entering nursing are well informed about genetics and are prepared to use emerging genomic information to improve patient outcomes. Nurse researchers might want to focus their scientific efforts on exploring the biological and behavioral aspects of symptoms such as pain and fatigue, with the goal of developing new knowledge and new strategies for improving patient health and quality of life (National Institute of Nursing Research, nd). Nurse administrators play a critical role, because they serve in key leadership roles as systems begin to integrate genomic discoveries into clinical settings in a meaningful way. Their support can accelerate nurses’ use of genomic information as it continues to emerge from large population based studies.

## 18.5. REFERENCES

- Aggarwal, B. B. (2004). Nuclear factor-kappaB: the enemy within. *Cancer Cell*, 6(3), 203–208. doi: 10.1016/j.ccr.2004.09.003
- Ahlberg, K., Ekmanb, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. *The Lancet*, 362(9384), 640–650. doi: 10.1016/S0140-6736(03)14186-4
- Aouizerat, B. E., Dodd, M., Lee, K., West, C., Paul, S. M., Cooper, B. A., . . . & Miaskowski, C. (2009). Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. *Biol Res Nurs*, 11(1), 27–41. doi: 10.1177/1099800409333871
- Aubrun, F., Langeron, O., Quesnel, C., Coriat, P., &

# Index

- 1000 Genomes Project, 240
- 21-hydroxylase deficiency (21-OH), 127
- 5-azacytidine, 259
- AAT deficiency (AATD), 190, 191
- AAT inhalation therapy, 191
- ABO blood types, 19, 20
- achondroplasia, 57, 155, 161
- Acquired Bone Marrow Failure Syndromes (ABMFS), 255, 279
- acrocentric, 3, 9
- acute lymphocytic leukemia (ALL), 281, 282
- acute myeloid leukemia (AML), 281
- acute promyelocytic leukemia (APL), 281, 282
- A Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTS13), 270
- adenine, 2, 10, 12, 261, 294, 301
- adenocarcinoma, 201–203, 368, 369, 381, 382, 385
- ADCY9*, 196
- adolescent cataracts, 299
- adrenal gland, 127
- adrenocorticotrophic hormone (ACTH), 127
- Agency for Healthcare Research and Quality (AHRQ), 413
- allergens, 196–198
- alpha thalassemia ( $\alpha$ -thal), 27, 258
- Alpha-1 antitrypsin (AAT), 189, 190
- alpha globin ( $\alpha$ -globin), 256–258
- Alport syndrome, 303, 305
- Alstrom syndrome, 305
- alternative splice sites, 13
- Alzheimer's disease, 26, 94, 96, 179, 183, 184
- ambiguous, 53, 128, 144, 239, 241, 328
- American Academy of Family Physicians (AAFP), 125, 168
- American Congress of Obstetrics and Gynecologists (ACOG), 125
- American Nurses Credentialing Center (ANCC), 73, 414, 425
- American Organization of Nurse Executives (AONE), 413
- American Society for Pain Management Nursing (ASPMN), 425
- amino acid, 10–13, 15–18, 142, 192, 198, 217, 219, 256–258, 290, 292, 301
- Amsterdam criteria (I and II) and colon cancer, 380
- amyotrophic lateral sclerosis (ALS), 289, 312, 313, 316,
- analgesic response, 428
- anaphase, 4, 6, 350
- ancestry of origin, 31, 42, 48–50, 371
- anencephaly, 26, 126
- aneuploidy, 68, 130, 136, 360, 369
- Angelman syndrome (AS), 24, 125, 131
- anorexia nervosa, 127
- antenatal steroids, 195
- anticipation, 25, 31, 56, 57, 78
- antiphospholipid antibody syndrome (APS), 276
- antisense strand, 10–12, 15–18
- antithrombin deficiency, 275, 277
- aplastic anemia, 268, 279
- apoptosis, 4, 126, 129, 180, 216, 301, 304, 306, 311, 313, 328, 345, 348, 350, 352–356, 358, 360
- applied behavioral analysis (ABA), 166, 168
- ASD-related syndromes, 167
- Ashkenazi Jewish Ancestry, 366, 371, 372, 375
- Asian, 18, 48, 75, 110, 114, 133, 190, 191, 200, 203, 210, 212, 215, 220, 221, 243, 260, 374, 384
- assisted reproductive technologies (ART), 71, 131
- assortative mating, 21
- asthma, 22, 24, 189, 190, 191, 196–200, 335, 426
- astrocytoma, 299, 364
- atherosclerosis/arteriosclerosis, 40, 209, 211, 214, 216, 223–226, 230, 242, 253
- atopic dermatitis, 196, 335
- attention-deficit/hyperactivity disorder (AD/HD), 164
- atypical HUS (aHUS), 270
- autism, 27, 44, 68, 125, 127, 164–166, 167, 169, 295, 296
- autism spectrum disorders (ASD), 68, 164, 166, 173
- autism-specific screening, 165
- Autoimmune Polyendocrine Syndrome Type 1, APS, 1, 328
- Autoimmune Polyendocrine Syndrome Type 2, APS, 2, 328
- Autoimmune Polyendocrine Syndrome Type 3, APS, 3, 328
- autoimmune regulator (AIRE), 328
- autonomy, 85–94, 172, 185, 388, 394
- autosome, 2, 8, 19
- base pairs, 211, 215, 243, 358, 359, 392

- basophils, 255, 264, 284
- Bacterial Inhibition Assay (BIA), 141, 142, 291
- Baye's Theorem, 73
- BCR/ABL* translocation (Philadelphia chromosome), 353
- Beckwith-Wiedemann syndrome, 131, 158, 161, 162
- Bernard-Soulier Syndrome (BSS), 272
- beta thalassemia ( $\beta$ -thal), 143, 256, 258
- beta globin ( $\beta$ -globin), 17, 70, 256–259
- Bethesda guideines, 380–383
- biallelic, 125, 279, 363
- biobanks, 414
- bioinformatic programs, 240, 249
- biological treatments, 424
- Birt-Hogg-Dube Syndrome (BHDS), 204
- bone marrow failure syndrome, 255, 268, 277, 279, 280
- BRAF V600E* mutation and colon cancer, 102, 201, 354, 383, 391
- brain tumors, 199298
- Branchio-Oto-Renal syndrome (BOR), 305
- bronchi, 203, 361
- Brugada Syndrome, 225, 244, 245
- Burkitt lymphoma, 285
- café au lait spots, 20, 152, 297–299, 364
- Canavan disease, 21
- Cancer Genomics, 345–407
  - BRCA genes (see Cancer Genomics—Hereditary Breast and Ovarian Cancer)
  - cancer, multistage genetic and genomic process, 358–360
  - cancer stem cells, 349, 350
  - cancer types and causes, 360–361
  - carcinogens (examples of), 360–361
  - carcinogenesis primer, 15, 345, 348–353, 355, 356, 358, 366, 378
  - caretaker genes, 355
  - characteristics of cancer cells, 353, 360
  - chromosomal instability pathway, 358–360
  - clonal cell evolution theory, 349
  - congenital hypertrophy of the retinal pigment epithelium (CHRPE), 385–386
  - Cowden's Syndrome, 362, 371–372, 378, 385, 395–396
  - de novo and cancer genomics, 363–365, 385
  - Definition of Common Terms used in Cancer Genetics, 345–346
  - Desmoid tumors, 385
  - direct to consumer testing, 72, 393
  - DNA repair genes, 356
  - DNA methylation (hypermethylation), 23, 127, 181, 356, 392, 420, 421
  - Empiric Risk Models for Breast Cancer (Gail and Claus), 374
  - endometrial cancer, 45, 371–373, 379, 381, 383, 384, 395, 396
  - epigenetics, 13, 23, 125, 126, 135, 168, 181, 242, 332, 333, 345, 348, 356, 357, 421
  - epigenomics, 417, 419–421
  - epithelial cell adhesion molecule gene (EpCAM), 363, 378, 380, 383, 384, 389
  - ethical, legal and social implications of single gene testing for hereditary colon cancer syndromes, 388–389, 391, 394 (biomarkers)
  - evaluation of Genomic Application in Practice and Prevention (EGAPP) and Lynch Syndrome, 383–384
  - exome sequencing, 33, 36, 70, 144, 240, 241, 390, 417, 418
  - familial cancer, 345, 351, 397
  - future advances and technologies and genomics of cancer, 389–392
    - exome sequencing, 33, 36, 70, 144, 240, 241, 390, 417, 418
    - genome wide associated studies, 391
    - next generation sequencing (NGS) and panel testing, 389–390, 391
    - tumor markers, 391–392
    - Whole genome sequencing, 391
  - gain-of-function, 328
  - gatekeeper genes, 355
  - genetic mutations, 198, 244, 270, 272, 283, 293, 296, 298, 304, 307, 311, 331, 339, 349, 352, 358, 360, 364
  - genetic mutations and Cancer Development, 351
  - Hereditary Breast Cancer Syndromes (including HBOC and other syndromes), 41, 60, 365, 372, 375, 376
    - data collection (personal/family history; physical examination) 370–372
  - Hereditary Breast and Ovarian Cancer syndrome (HBOC) (BRCA gene mutations), 41, 54, 56, 365, 367
    - genetic testing, 374
    - Identification of Risk Elements and Red next generation sequencing (NGS), 389–390
    - Other Data Collection Resources, 372
    - primary prevention, 376–377
    - RAPID approach to assessment, 394–397
    - risk probability, 372–374
  - Risk Probability Models (i.e. BRCAPRO, BOADICEA), 372–374
    - Secondary Prevention and enhanced Surveillance, 377
  - Hereditary Cancer, 345, 351, 352, 362–365, (Breast and Ovarian, 365–378), (Colon Cancer, 378–388)



- Hereditary Colon Cancer Syndromes, 363, 378–388
- Lynch Syndrome, 363, 378–385
- introduction 378
  - differential diagnoses and Lynch Syndrome, 385
  - management, 384
  - phenotype and characteristics (Colon), 378–379
  - phenotype and characteristics (Extracolonic [e.g. endometrial; ovarian]), 379–380
  - Risk Assessment and Identifying individuals
  - suspect for Lynch, 380
  - variants of Lynch Syndrome (Muir-Torre and Turcot), 380
- polyposis syndromes, 378, 385
- Familial Adenomatous Polyposis (FAP) and Attenuated FAP, 385–386
- Gardner's syndrome, 386
- Turcot syndrome, 380, 386
- MUTYH-associated polyposis (MAP), 363, 386
  - Other Hereditary Colon Cancer Syndromes not associated with adenomatous, 386–388
- Peutz-Jeghers (e.g. hamartomatous polyps), 378, 386, 388
- juvenile polyposis, (e.g. juvenile polyps) 363, 378, 387
- immunohistochemical (IHC) staining, 379
- Knudson's two-hit hypothesis 354–355, 366
- KRAS* mutations, 392
- loss-of-function, 112, 113, 328
- loss of heterozygosity, 354
- loss of homozygosity, 354
- microRNA, 345, 358, 359, 392
- microsatellites, 357, 379
- microsatellite instability, 379
- mismatched repair genes (MMR), 360, 378, 379, 380, 383
- molecular genomic make-up, 347
- Muir-Torre Syndrome (See variants of Lynch Syndrome)
- MUTYH-associated polyposis (See polyposis syndromes)
- next generation sequencing (NGS), 389, 390
- online/web-based resources, 396
- ovarian cancer, 379–380
- p53 Tumor Suppressor gene, 350, 354–356, 359, 362, 364
- personalized care, 347, 349, 360, 376, 389, 390, 392
- pharmacogenomics and cancer, *also refer* to Chapter 5 (5-Fluorouracil; Irinotecan; Mercaptopurine), 103–108
- irinotecan, 393
  - Tamoxifen, 392–393
  - Thiopurines, 393
- precision medicine, 348, 349, 360, 389, 390
- Precision Medicine Initiative, 348
- proto-oncogenes, oncogenes and carcinogenesis, 346, 352–353
- RAPID Approach and Cancer Genomics, 369–376; Utilization of RAPID for breast cancer, 394–395; (*See also* Chapter 2)
- retinoblastoma, 354
- Risk Assessment and Cancer Genomics 369–376
- Data Collection (Personal and Family History and Physical Examination), 370–372
- Risk Identification and Risk Elements, 372
- Risk Probability, 372–374
- Risk Communication/Counseling and Risk Management, 375–376
- sex cord tumors with annular tubules (SCTAT), 386
- somatic mutation, 351, 354, 362, 366
- sporadic cancer, 346, 351, 354, 356, 362, 369
- statistical trend data incidence and mortality, 346–347
- stem cell theory, 349
- tumor suppressor genes, 352, 353–356
- tumor markers and breast cancer (*Example of*), 391–392
- tumor markers and colon cancer (*Example of*), 392
- Turcot Syndrome (*See variants of Lynch Syndrome*) cancer, multistage genetic and genomic process, 358–360
- cancer related fatigue (CRF), 423, 425
- cancer stem cells, 349, 350
- cancer types and causes, 360–361
- candidate genes, 426
- cardiac channelopathies, 244–245
- cardiovascular pharmacogenomics, 109
- caring, 7, 80, 86, 91, 123, 132, 168, 169, 250, 292, 415
- carrier rate, 21
- carrier screening, 21, 71
- carcinogens (examples of), 51, 200, 361
- carcinogenesis primer, 348–351
- caretaker genes, 355
- catch-down growth, 155
- catch-up growth, 155
- catecholaminergic polymorphic ventricular tachycardia (CPVT), 244–245
- celiac disease, 129, 153, 157, 330, 331, 335, 336
- cell cycle, 4, 5, 22, 181, 277, 278, 345–360, 364, 366
- cell free fetal (cff) DNA testing, 136
- cell membrane disorders, 255, 259
- Centers for Disease Control and Prevention (CDC), 28, 35, 63, 73, 141, 150

- central dogma, 12
- centrioles, 4, 7
- centromere, 2–6, 9, 10
- CF transmembrane conductance regulator (CFTR), 102, 130, 135, 192, 193, 203
- CF-related diabetes (CFRD), 192
- characteristics of cancer cells, 360
- Chediak-Higashi syndrome (CHS), 265, 272
- CHEK2*, 200, 389
- chemokines, 197
- chemotherapy, 104, 106, 114, 203, 262, 267, 278, 282, 300, 391, 392, 393, 424
- childhood bronchiectasis, 194
- childhood leukemia, 126
- chloride channels, 192
- chorea, 57, 301–303
- chorionic villus sampling [CVS], 136, 150
- Chromatid, 4–7, 350
- chromosomal instability pathway, 358–360
- chromosomal microarray, 68
- chromosome microarray, 149
- chronic bronchitis, 191
- chronic inflammation, 257, 427
- chronic lymphocytic leukemia (CLL), 269, 281, 283
- chronic myeloid leukemia (CML), 281, 282
- chronic obstructive pulmonary disease (COPD), 189
- chronic pain, 257, 299, 309, 425–428
- chronic sinus infection, 130, 194
- Chuvash polycythemia (CP), 262
- ciliary bodies, 194
- Circadian Locomotor Output Cycles Kaput genes, CLOCK genes, 336, 337
- cleft lip and palate, 25, 153
- client focused counseling, 67, 74
- Clinical Pharmacology and Therapeutics Implementation Consortium, 105
- clinical practice knowledge, 413–414
- ClinSeq Project, 418–420
- clonal cell evolution theory, 349
- C-myc oncogene, 285
- coagulopathies, 255, 274–275
- codominant, 19, 108, 190
- codon, 10–13, 17, 18, 258, 301
- cognition, 19, 35, 52, 59, 128, 150, 164–166, 259, 262, 347, 371, 384
- common complex diseases, 32, 41, 181, 209
- communication disorders, 166, 317
- communication patterns, 75
- compound heterozygous, 104
- Comprehensive Cancer Network (CCN), 38, 199, 282, 284, 348, 396, 423
- comprehensive health history, 411
- Congenital Adrenal Hyperplasia (CAH), 127, 135, 142, 159, 327, 328, 330
- congenital amegakaryocytic thrombocytopenia (CAMT), 268, 279
- congenital dyserythropoietic anemias (CDA), 278
- congenital heart defects, 52, 129, 141, 153
- congenital heart disease, 26, 142, 152, 155, 243
- congenital hypertrophy of the retinal pigment epithelium (CHRPE), 385–386
- congenital hypothyroidism, 142
- connective tissue disorders, 242–243
- connexin, 304
- consanguinity, 21, 31, 32, 42, 45, 49, 150, 266, 267, 277, 380
- consent, 44, 69–71, 75, 77, 87, 92, 94, 136, 141, 144–146, 170, 204, 382, 388, 390, 392, 412
- consequentialism, 86
- constitutional growth delay, 157
- consultant, 48, 54
- context, 52, 74, 75, 79, 85–88, 93, 95, 107, 124, 155, 157, 184, 185, 212, 215, 217, 223, 231, 412, 417, 418, 420
- Coordinating Center of the Newborn Screening Translational Research Network (NBSTRN), 145
- copy number variant (CNV), 68, 127, 167, 203, 242
- Cornelia DeLange syndrome (CdLS), 155
- Coronary Artery Disease (CAD), 40, 209–212, 225, 226, 239
- Cowden Syndrome, 362, 371–372, 378, 385, 395–396
- CpG islands, 23, 420
- craniopharyngioma, 157
- cri du chat, 153
- crossing over, 5, 6, 10
- cryopreservation, 131
- cryptorchidism, 127, 152
- cultural background, 42, 74
- Cushing disease, 157
- cyclo-oxygenase 1 (COX1), 271
- CYP11A1*, 126
- CYP2C19*, 101, 111–113, 116
- CYP2C9*, 101, 109–111, 116, 225
- CYP3A5*, 196
- CYP3A7*, 196
- Cystic Fibrosis (CF), 13, 21, 25, 40, 71, 91, 96, 124, 130, 132, 135, 143, 146, 157, 189, 190–193, 197, 413
- CF Foundation, 190
- cytogenetics, 6, 68, 282, 284
- cytokines, 134, 197, 261, 266, 339, 350, 358, 424
- cytosine, 2, 10, 23, 30, 420
- cytotoxic chemotherapy, 424
- Data Collection (Personal and Family History and Physical Examination), 370–372
- de novo and cancer genomics, 363–365, 385

- de novo (new) mutation, 19, 20, 23, 32, 56–58, 162, 167, 180, 243, 297, 298
- decision-making, 33, 35, 37, 58, 85–90, 92, 93, 94, 144, 185, 240, 306, 360, 376, 388, 391, 394, 414, 419
- decitabine, 259
- Definition of Common Terms used in Cancer Genetics, 345–346
- deletion syndrome (congenital cardiac anomaly), 243
- dendritic cells, 255, 266, 277
- deontologic, 86
- deoxyribonucleic Acid (DNA), 1, 167
- depression, 44, 78, 111, 127, 134, 180, 268, 296, 302, 303, 312, 393, 414, 423
- Desmoid tumors, 385
- desmopressin (DDAVP), 271
- development, 1, 20, 28, 52, 53, 90, 103, 125, 130, 144, 150, 153, 165, 166, 172, 196, 198, 214, 219, 250, 291, 292, 296, 304, 305, 313, 315, 331, 348, 360
- developmental delays, 149, 150, 152, 165, 198, 296
- developmental domains, 165
- developmental milestones, 164, 291
- developmental surveillance, 165
- dextrocardia, 194
- diakenesis, 5
- Diamond-Blackfan anemia (DBA), 279
- differential diagnoses and Lynch Syndrome, 385
- Disseminated Intravascular Coagulation (DIC), 268
- dihydropyrimidine dehydrogenase gene (DPD) and DPD deficiency, 104, 105
- dihydropyrimidine dehydrogenase gene (DPYD), 104
- diplotene, 5
- Direct To Consumer (DTC), 72, 227
- direct to consumer testing, 72, 393
- DNA methylation (hypermethylation), 23, 127, 181, 356, 392, 420, 421
- DNA repair genes, 356
- DNA sequence analysis, 70, 72
- DNA sequencing technologies, 143
- Down syndrome (DS), 9, 153, 159, 161, 280
- dried blood spots, 141–146
- drug-induced thrombocytopenia, 269
- Duchenne Muscular Dystrophy, 22, 45, 242
- duplications, 10, 68, 128, 168, 298, 304
- Dyskeratosis Congenita (DC), 265, 277, 278
- dyslipidemias, 214
- dysmorphology, 32, 52, 53, 149, 150, 166
- early intervention, 136, 165, 172, 306
- early onset Parkinson disease, 310
- East Asian, 133, 221, 260
- eclampsia, 130–134, 219
- Evaluation of Genomic Application in Practice (EGAPP), 79, 106, 211, 227, 229, 383, 384, 412
- Ehlers-Danlos Syndrome (EDS), 243
- electronic medical records (EMRs), 34, 169, 414
- emphysema, 57, 189–191, 193,
- Empiric Risk Models for Breast Cancer (Gail and Claus), 34, 58, 374
- endometrial cancer, 45, 371–373, 379, 381, 383, 384, 395, 396
- environmental influences, 132, 191, 228, 239, 307, 327, 333, 335, 412, 413
- eosinophils, 255, 264
- ependymomas, 298, 299, 364
- epidermal growth factor receptor (EGFR), 41, 203, 369
- epigenetics, 13, 23, 125, 126, 135, 168, 181, 242, 332, 333, 345, 348, 356, 357, 421
- epigenomics, 417, 419–421
- epilepsy, 25, 126
- epithelial cell adhesion molecule gene (EpCAM), 363, 378, 380, 383, 384, 389
- epithelial cells, 197, 335
- erythrocytosis, 261, 262
- erythropoietin receptor (EPOR) gene, 261, 262
- essential hypertension, 209, 210, 218–223
- essential thrombocytosis, 271, 272, 283
- Ethical Legal and Social Implications (ELSI), 85, 89, 183, 348, 388, 394
- ethical, legal and social implications of single gene testing for hereditary colon cancer syndromes, 388–389, 391, 392 (biomarkers)
- Ethical Standards, 85, 88, 90
- ethics, 85–91, 96, 135, 183, 185, 412
- ethnic background, 52, 54, 74, 301, 313
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, 135, 144, 296
- evaluation of Genomic Application in Practice and Prevention (EGAPP) and Lynch Syndrome, 383–384
- evidence-based practice, 116, 184, 185
- excess growth, 157
- exome sequencing, 33, 36, 70, 144, 240, 241, 390, 417, 418
- exons, 12, 70, 190, 374, 390
- expansion mutation, 18, 25
- experience of pain, 426
- experiential background, 74, 75
- extreme longevity, 181
- F508del mutation, 192
- Factor XI deficiency, 274
- faculty, 100, 185, 409–413, 428
- false positive rates, 127
- Familial Adenomatous Polyposis (FAP) and Attenuated FAP, 348, 356, 363, 364, 378, 381, 386
- familial Amyotrophic Lateral Sclerosis (ALS), 314
- familial cancer, 345, 351, 397
- familial dilated cardiomyopathy, 242



- familial hypercholesterolemia, 44, 241, 247, 249, 250
- familial Parkinson disease, 311
- familial short stature, 155, 159
- family health history (FHH), 32, 37, 38, 45, 62, 90, 123, 124, 129, 183, 184, 203, 262, 334, 410, 411
- family relationships, 45, 46, 67, 75, 77
- Fanconi anemia (FA), 159, 277, 356, 366
- features of genetic syndromes, 151–153, 172
- fecundity, 127
- Federal Trade Commission, 73
- financial management, 413
- FLCN*, 204, 205, 364
- Florence Nightingale, 425
- fluorescent in situ hybridization (FISH), 68
- folic acid, 26, 126, 127, 260
- folic acid supplementation, 26, 126, 127, 260
- follicular lymphoma, 285
- Foundation for Sickle Cell Disease Research (FSCDR), 413
- foundational thinking skills, 414
- Fragile X premature ovarian insufficiency (FXPOI), 128, 296
- Fragile X syndrome (FXS), 18, 25, 45, 173, 295, 296, 315
- Fragile X-associated tremor, ataxia syndrome (FX-TAS), 296, 426
- frailty, 179, 180
- frameshift mutation, 17, 18, 297
- Friedreich's Ataxia (FRDA), 293–294
- frontotemporal dementia, 179
- full mutations, 128
- functional change, 18, 256, 360
- future advances and technologies and genomics of cancer, 389–393
- FVL*, 275, 276
- gain of function, 18, 245, 248, 263, 275, 328, 352, 353
- galactosemia, 142, 143
- gamma globin, 256
- Gardner's syndrome, 386
- gatekeeper genes, 355
- Gaucher, 21, 169, 267, 268
- gene therapy, 89, 191, 258, 259, 269, 312
- GeneQol Consortium, 425
- Genes associated with MS, 308–309
- genes in common pathways, 167
- genetic alliance, 78, 79, 96, 144, 240, 241
- genetic discrimination, 67, 240
- genetic/genomic competencies, 85, 124
- Genetic Information Nondiscrimination Act (GINA), 67, 94, 190, 240
- genetic mutations, 198, 244, 270, 272, 283, 293, 296, 298, 304, 307, 311, 331, 339, 349, 351, 352, 358, 360, 364
- genetic mutations and Cancer Development, 351
- genetic polymorphisms, 109, 110, 196, 424
- genetic predisposition, 54, 195, 199, 218, 242, 334
- genetic red flags, 415
- genetic risk assessment, 73
- genetic screening, 37, 38, 42, 71, 124, 136, 240, 247
- Genetics Interdisciplinary Faculty Training (GIFT), 410
- Genetics Program for Nursing Faculty (GPNF), 410
- genome sequencing, 33, 70, 80, 87, 96, 115, 116, 143, 229, 241, 249, 389, 391, 414, 417, 418, 421
- Genome Wide Association Studies (GWAS), 27, 191, 197, 210, 211, 309, 391, 426
- genomic imprinting, 24, 125, 331
- genomic literacy, 411
- Genomic Nursing State of the Science Advisory Panel, 412
- genomic risk assessment, 34, 149, 411
- genomic variants, 423
- germline mosaicism, 20, 23
- germline mutation, 20, 199, 204, 278, 378, 380
- gestational diabetes mellitus (GDM), 131
- GH excess, 158
- Gilbert's syndrome, 106
- Glanzmann's Thrombasthenia (GT), 272
- glucose-6-phosphate Dehydrogenase Deficiency (G6PD), 261
- glucuronidated SN-38, 105, 106
- glutathione S-transferase M1 (GSTM1), 200
- Glutathione S-transferase T1 (GSTT1), 200
- GPC5*, 200
- GPIIb/IIIa receptor, 271
- Grave's Disease (GD), 159, 327, 330
- Gray platelet syndrome, 272
- growth charts, 155, 157
- growth curves, 155
- growth factors, 197, 280, 352
- growth hormone deficiency, 153, 157
- growth potential, 155
- growth retardation, 157
- guanine, 2, 10, 12, 23, 107, 294, 301, 313, 393, 420
- Guthrie card, 141
- Hardy Weinberg calculation, 73
- Hashimoto's thyroiditis, 159, 327, 330, 412
- Hereditary Breast and Ovarian Cancer (HBOC), 19, 41, 54, 56, 57, 70, 362, 365–367, 371, 372
- HDAC inhibitors, 259
- health care economics, 413
- health care transition, 168, 170, 171, 173
- Health Insurance and Portability Accountability Act (HIPAA), 48, 49, 67, 92, 95, 372, 388, 414
- health outcomes, 28, 57, 60, 125, 132, 145, 196, 227, 340, 392, 413, 423
- health promotion and disease prevention, 57, 412
- hematologic neoplasms, 255, 280, 283

- hemoglobin (Hb), 16, 17, 132, 135, 143, 255–267, 332
- Hemoglobin Bart's Hydrops Fetalis, 258
- hemoglobin C (HbC), 256
- hemoglobin E (HbE), 256
- hemoglobin H disease, 258
- hemoglobin S (HbS), 256
- hemoglobinopathies, 134, 143, 255–260, 278
- hemolytic anemia, 18, 255–261, 270, 278, 280
- hemophagocytic lymphohistiocytosis (HLH), 267
- hemophilia, 22, 134, 272–275
- hemophilia A, 273, 274
- hemophilia B (Christmas disease), 274
- hepatitis B, 52, 195, 361
- hepcidin, 263, 264
- HER2* protein, 114
- Hereditary Breast and Ovarian Cancer syndrome (HBOC) (BRCA gene mutations), 19, 41, 70, 76, 77, 348, 366, 372, 375, 376
- Hereditary Breast Cancer Syndromes (including HBOC and other syndromes), 41, 60, 365, 372, 375, 376
- Hereditary Cancer, 345, 351, 352, 362–365, (Breast and Ovarian, 365–378), (Colon Cancer, 378–388)
- Hereditary Colon Cancer Syndromes, 378, 380, 383, 385, 388
- Hereditary elliptocytosis (HE), 260
- Hereditary Hemochromatosis (HH), 50, 263
- hereditary persistence of fetal hemoglobin (HPFH), 256
- hereditary spherocytosis (HS), 260, 278
- heritability, 27, 72, 167, 178, 196, 210, 212, 213, 215, 218, 331, 334, 426
- heritability of aging, 178
- Hermansky-Pudlak syndrome (HPS), 265, 272
- heterogeneity, 19, 53, 70, 209, 221, 229, 249, 260, 272, 349, 389, 390, 392, 425, 427
- heterotaxy, 194
- heterozygous, 19, 104, 105, 107, 108, 109, 217, 248, 249, 265, 267, 275, 283, 329, 354, 386
- HFE*, 48, 50, 51, 55, 62, 263
- Hispanic, 26, 42, 48, 75, 91, 126, 191, 195, 210, 243, 247, 366
- histiocytes, 255, 266
- histone inhibitor, 127
- histone modification, 13, 181, 420
- HLA-A class I major histocompatibility genes, 203
- Hodgkin, 52, 285
- Homozygous, 13, 35, 104–109, 217, 224, 249, 257, 262, 263, 266, 275, 276, 283, 329, 366
- horizontal transmission, 32, 50
- HSC transplantation, 258, 259, 262, 282
- Human Immunodeficiency Virus (HIV), 18, 99, 113, 141, 268, 361
- Human Leukocyte Antigen (HLA), 114, 258, 308, 309, 329
- HLA-B\*5701*, 113, 114, 308
- human resource management, 413, 414
- Huntington disease (HD), 18, 40, 77, 179, 289, 300–302, 418
- Huntington Disease Society of America, 302
- hypergonadotropic hypogonadism, 130
- hyperimmunoglobulin E syndrome, 266
- hypermethylates, 128
- hypersensitivity reaction, 113
- hypertrophic cardiomyopathy, 225, 242, 245, 247, 250, 294
- hyperviscosity, 262
- hypothyroidism, 129, 142, 157
- hypoxia-inducible factor-alpha (HIF1- $\alpha$ ), 262
- Identification of Risk Elements and Red next generation sequencing (NGS), 389–390
- immune Dysregulation Polyendocrinopathy, Enteropathy, X-linked Syndrome, IPEX Syndrome, 329
- immune-mediated asthma, 197
- immunohistochemical (IHC) staining, 379
- importin-beta, 196
- imprinting, 24, 125, 131, 135, 331
- incidental findings, 69, 70, 71, 77, 87, 89, 144, 146, 418
- infectious disease, 102, 113, 194, 195
- infertility, 10, 40, 42, 44, 46, 54, 68, 27, 129–131, 134, 162, 163, 192, 296
- inflammation, 189, 197, 214, 307, 314, 332, 335, 336, 427
- inflammatory bowel disease, 72, 159, 380
- inflammatory mediators, 197
- inflammatory response, 427
- information technology, 412, 4114
- informed consent, 44, 69–71, 75, 76, 87, 92, 94, 136, 144, 204, 388, 390, 396, 412
- inherited bleeding disorders, 134
- Inherited Bone Marrow Failure Syndromes (IBMFS), 277
- innate immunity, 197, 200, 264
- innovation, 95, 96, 424
- insertion, 17, 18, 27, 202, 204, 220, 226, 259, 280, 282, 294, 304, 311, 378, 391
- insulin-like growth factor-1 (IGF-1), 427
- intellectual developmental disorders, 166
- intellectual disability (ID), 53, 128, 153, 167, 198, 291, 295, 296
- interactome, 35
- interleukin (IL), 197, 275, 308, 309, 424
- International Standard Cytogenomic Consortium, 69
- Interphase, 5, 6, 283
- interpretation of sequence analysis, 70

- intracytoplasmic sperm injection (ICSI), 131, 163  
 intramural training, 413  
 intravenous human plasma-derived augmentation therapy, 191  
 Introns, 12, 14, 70, 417  
*IPO13*, 196  
 IQ, 130, 163, 165–158, 160, 161, 163, 164  
 irinotecan, 99, 101, 105, 106, 107, 393  
 Irish, 18, 133  
 iron overload disorders, 264  
  
*JAK/STAT* pathway, 262  
*JAK1/JAK2*, 284  
 Japanese, 205  
 Jervall and Lange-Nielsen, T13.2, 305  
 Job syndrome, 266  
 justice, 85–91, 388, 391  
 juvenile HD, 302  
 Juvenile deafness, 54  
 juvenile idiopathic arthritis, 159  
 juvenile polyposis, (e.g. juvenile polyps), 363, 378, 387  
  
 karyotype, 24, 32, 46, 68, 157–160, 163, 282, 283  
*KRAS* mutations, 202, 203, 392  
 Klinefelter syndrome, 130, 35, 158, 161–164  
 Knudson's two-hit hypothesis 354  
*KRAS*, 61, 102, 199, 202, 203, 392  
  
 Langerhans cell histiocytosis (LCH), 267  
 large-cell lung cancer, 203  
 Le Fraumini, 199  
 leadership, 34, 89, 182–184, 327, 409, 412, 413, 414, 428  
 learning disabilities, 20, 44, 54, 125, 128–130, 152, 154, 164, 166, 295–296, 298, 331  
 leprosy, 195  
 leptokene, 5  
 Leukocyte adhesion deficiency (LAD), 266  
 Lisch nodules, 154, 298, 364  
 literacy, 44, 74, 80, 92, 96, 185, 411  
 liver disease, 191, 274  
 locus, 19, 70, 209, 211, 212, 230, 245, 362  
 Loeys-Dietz Syndrome (LDS), 243  
 Long QT Syndrome (LQTS), 215, 225, 244  
 long-term storage, 145  
 loss of function, 18, 24, 103, 112, 113, 245, 248, 271, 275, 299, 328, 353, 354, 355  
 loss of heterozygosity, 354  
 loss of homozygosity, 354  
 lymphocytes, 68, 255, 264, 267, 275, 283, 284, 329, 379, 381  
 lymphomas, 284, 285  
 Lynch Syndrome, 363, 378–385  
 Lysosomal Storage Disorders, 267  
  
 Manager Inventory Tool, 413, 415  
 mannose-binding lectin 2 (MBL2), 192  
 mantle cell lymphoma, 285  
 March of Dimes, 38, 96, 142  
 Marfan Syndrome (MFS), 155, 158, 161–165, 223, 224, 243, 328  
 massive parallel sequencing, 70  
 maternal copy, 1257  
 maternal phenylketonuria, 133  
 May-Hegglin anomaly, 268  
 Medicaid, 38, 172, 41  
 Medicare, 38, 172, 414  
 meiosis, 1, 5–7, 10, 22, 24, 25, 295,  
 meiosis II, 6  
 MELAS, 25, 33, 305  
 Mendelian inheritance, 19, 32, 48, 56, 61, 182, 184, 239, 337, 366, 417, 420  
 meningioma, 298, 300, 361  
 menopause, 68, 126, 296  
 mental health disorders, 127  
 messenger RNA (mRNA), 10, 358, 418  
 metabolic disorders, 21, 24, 126, 150, 264, 267  
 metabolomics, 99, 209, 215, 217, 222, 223, 229  
 metacentric, 3,  
 metaphase, 4–6 68, 284, 350, 358  
 methylation, 13, 23, 28, 107, 127, 181, 225, 137, 225, 295, 296, 326, 345, 354–358, 363, 378, 383, 392, 420, 421  
 microbiome, 72, 334  
 microfluidic chip, 143  
 microRNA, 14, 250, 311, 333, 345, 358, 359, 419, 420  
 microsatellites, 357, 379  
 microsatellite instability, 358, 379  
 mid-parental height, 157, 160  
 miscarriage, 40, 42, 44, 129  
 missense mutation, 16, 19, 219, 220, 304, 311  
 mitochondria, 1, 25–27, 126, 168, 181, 261, 293, 303–306, 311, 362, 425  
 mitochondrial disease, 126  
 mitochondrial DNA (mtDNA), 1, 26, 3050  
 mitochondrial encephalomyopathy, lactic acidosis and stroke=like episodes (MEILAS), 305  
 mitochondrial inheritance, 25, 27  
 mitosis, 1, 4–6, 350, 360  
 mode of inheritance, 161, 414  
 modifier genes, 25, 192, 197,  
 molecular genetics, 282, 317, 410, 413, 424  
 molecular genomic makeup, 347  
 molecular testing, 143, 146, 375  
 monocytes, 264, 427  
 Monogenic Diabetes, maturity-onset diabetes, MODY, 327, 328, 331, 338, 339  
 monosomy, 8, 10, 22  
 mosaic, 8, 20, 23, 129, 173, 297

- mosaicism, 8, 20, 23, 130, 173  
 motor disorder, 166  
 Muir-Torre Syndrome (See variants of Lynch Syndrome) multifactorial inheritance, 378, 380  
 multigenic, 167  
 Multiple Endocrine Neoplasia Type 1, MEN1, 327, 328  
 Multiple Endocrine Neoplasia Type 2, MEN2, 328, 364  
 multiple myeloma, 284, 356  
 multiple sclerosis (MS), 289, 303, 307–310, 316, 317  
 muscular dystrophy, 222, 45, 242  
 mutation detection rate, 70  
 MUTYH-associated polyposis (MAP), 363, 386  
 mycobacterium tuberculosis, 195  
 myelodysplastic syndromes, 280  
 myelokathexis, 265, 285  
 myeloproliferative neoplasm (MPN), 262, 271, 272, 276, 283  
 myocardial infarction and survival, 112, 210, 214–215, 225, 226, 275  
 myoclonic epilepsy with ragged red fibers, 25  
 myotonic dystrophy, 13, 18, 31  
 National Association for Retarded Citizens, 142  
 NCLEX (National Council Licensure Examination), 414  
 NHGRI (National Human Genome Research Institute), 2–8, 12–14, 26, 28, 69, 94, 95, 159, 160, 211, 357, 391  
 National Institute of Nursing Research (NINR), 115, 410, 413, 428  
 National Newborn Screening and Genetics Resource Center, 142  
 National Research Council of the National Academy of Science (NAS/NRC), 142  
 National Society of Genetic Counselors (NSGC), 38, 59, 73  
 negative selection, 328  
 Neonatal alloimmune thrombocytopenia (NAIT), 270  
 neonatal respiratory distress syndrome (RDS), 195  
 NDI (Nephrogenic Diabetes Insipidus), 329  
 neural tube defect, 26, 126  
 neurodevelopmental disorder (NDD), 166, 172  
 neurofibromas, 20, 52, 154, 300  
 neurofibromatosis, 20, 56, 126, 153, 173, 289, 297, 299, 305, 315, 316, 364  
 Neurofibromatosis Type 1 (NF1), 297  
 Neurofibromatosis Type 2 (NF2), 297  
 neuroplasticity, 165, 168  
 neuropsychiatric disorder, 167  
 neutropenia, 105–107, 264–266, 277, 279, 280, 393  
 neutrophil elastase (NE), 189, 191, 279  
 neutrophils, 190, 255, 264–266  
 newborn hearing screening, 306  
 newborn screening, 40, 70, 71, 77, 79, 133, 141–146, 193, 289, 291, 296, 411  
 Newborn Screening Quality Assurance Program (NSQAP), 143  
 next generation sequencing, 70, 71, 77, 80, 224, 225, 348, 389, 417, 418  
 next generation sequencing (NGS) and panel testing, 389–391  
 Niemann-Pick disease, 267  
 NHLBI (National Heart, Lung and Blood Institute Exome Sequencing Project), 240  
 nitrogenous base, 1  
 nociceptor modifications, 428  
 nondisjunction, 7–9, 352  
 non-Hodgkin lymphoma (NHL), 52, 285  
 nonmaleficence, 85, 87, 89, 90, 412  
 nonsense mutation, 16, 17, 297  
 non-small cell lung cancer (NSCLC), 190, 200–202  
 nonstructural single gene disorders, 239, 244  
 Northern European Caucasian, 130, 190, 191, 193, 260  
 noxious stimuli, 426  
 nuclear DNA (nDNA), 1, 2, 25, 181, 293  
 nuclear membrane, 4–6  
 nucleotide, 1, 4, 15, 27, 72, 127, 128, 167, 181, 211, 220, 223, 229, 259, 282, 313, 332, 348, 356, 358, 390–392, 417, 419, 423  
 numeracy, 74, 80  
 nurse administrators, 185  
 nurse researchers, 34, 61, 100, 116, 146, 409, 412, 413, 428  
 National Institute of Nursing Research (NINR), 115, 410, 413, 428  
 nursing research, 89, 115, 409, 410, 412, 413, 428  
 obesity, 331, 332, 333, 334, 335, 336, 337, 339(t)  
 obstructive sleep apnea (OSA), 262  
 occupational fumes, 189, 191  
 oncogene, 199–203, 285, 328, 345, 346, 352–355, 358, 365, 419, 421  
 oncology pharmacogenomics 103,  
 online resources, 28, 182, 190, 337, 396, 417  
 opt-out, 144  
 optic gliomas, 298, 300  
 osteogenesis imperfecta, 305  
 Other Data Collection Resources, 372  
 Other Hereditary Colon Cancer Syndromes not associated with adenomatous , 383  
 ovarian cancer, 12, 19, 25, 41, 54, 56, 57, 70, 348, 365–369, 371–380, 384, 385, 394, 395, 425  
 p53 Tumor Suppressor gene, 350, 354–356, 359, 362, 364  
 pan cardio panel, 224, 225, 241  
 pancreatic exocrine insufficiency, 192  
 Parkinson disease, 26, 310

- p arm, 2
- pachytene, 5, 6
- pain, perception of, 426, 427
- pain management, 425–428
- pain phenotypes, 427
- pain processing, 291, 427
- pain sensitivity, 426, 428
- pan ethnic, 130
- pancytopenia, 267, 268, 277–279
- paracentric inversion, 10
- paroxysmal nocturnal hemoglobinuria, 271, 272, 276, 280
- patau syndrome (Trisomy 13), 153
- paternal age, 126, 134, 136
- paternal genes, 125, 133
- paternal malnutrition, 125
- paternal smoking, 126
- pathologic chromosomal abnormalities, 159
- penetrance, 19, 20, 31, 32, 37, 56–58, 69, 71, 72, 239, 274, 276, 295, 297, 301, 305, 367, 384, 385, 389
- performance improvement, 413, 414
- pericentric inversion, 10
- peripartum depression (PPD), 134
- peripheral inflammation, 427
- personal history, 32, 41, 42, 44, 58, 61, 126, 276, 363, 364, 370, 374, 380, 389
- personalized care, 33, 54, 62, 115, 345, 394, 417, 428
- personalized medicine, 99, 100, 113, 240, 391, 392, 412
- Peutz Jeghers, 362, 363, 378, 386, 388
- pharmacodynamics, 102, 103, 217
- pharmacogenetics, 79, 100, 102, 110, 113–115, 2210, 217, 223, 229
- pharmacogenomics and cancer, *also refer to* Chapter 5 (5-Fluorouracil; Irinotecan; Mercaptopurine), 103–108
- pharmacokinetics, 101, 103
- PHE, teratogenic effect, 292
- phenotype and characteristics (Colon), 378–379
- phenotype and characteristics (Extracolonic [e.g. endometrial; ovarian]), 379–380
- phenotypic heterogeneity, 390, 425, 427
- phenylalanine (PHE), 11, 133, 141, 192, 290, 291, 293
- phenylalanine hydroxylase (PAH), 290, 291
- phenylketonuria (PKU), 124, 125, 133, 135
- Pick's disease, 179
- PIK3CA activating mutations, 203
- PKU diet, 291, 292
- placentation, 134
- plasticity, 166, 295, 427
- platelet closure time (PFA-100), 271
- platelet disorders, 255, 268, 269, 271, 272
- pluripotent stem (iPS) cells, 250, 255, 259
- pneumonia, 191, 194, 301, 312
- point mutation, 70, 128, 199, 282, 294, 295, 296, 304, 311, 352
- point-of-care (POC), 141
- Poliomyelitis, 195
- poly-A tail, 12
- polycyclic aromatic hydrocarbons, 126, 200
- Polycythemia, 255, 261, 262, 275, 283
- Polycythemia Vera (PV), 262
- polyposis syndromes, 378, 385
- pomalidomide, 259
- population-based screening, 142
- porphyrias, 264
- positive predictive value, 76, 227
- postpartum hemorrhage (PPH), 134
- Post-transfusion purpura (PTP), 269
- Potocki-Lupski syndrome, 167
- Prader-Willi syndrome (PWS), 28, 125, 155, 161, 331, 339
- precision care, 60, 360
- precision medicine, 32, 34, 36, 99, 100, 103, 107, 109, 113, 348, 349, 425
- Precision Medicine Initiative, 348
- precocious puberty, 128, 158, 328
- preconception care, 123–125, 135
- preconceptional counseling, 124–126, 132–133
- predictive biomarkers, 100
- predictive testing, 72, 76, 77, 78, 179, 388
- preeclampsia, 130, 131, 133, 134, 219
- preimplantation genetic diagnosis (PGD), 131
- premature aging, 180, 181
- premature ovarian insufficiency, 128, 129
- premutation, 25, 128, 294–296
- premutation carriers, 128, 295
- prenatal education, 92, 124
- prenatal screening, 71, 123, 135, 136, 258, 314
- prenatal testing, 92, 136, 150, 299
- presymptomatic testing, 33, 72, 141
- primary ciliary dyskinesia (PCD), 194
- primary familial and congenital polycythemia/erythrocytosis (PFCP/Erythrocytosis), 261
- primary myelofibrosis, 284
- primary prevention, 246, 376
- primary screening test, 143
- probability, 21, 23, 32, 33–36, 50, 57–62, 73, 127, 149, 347, 365, 370, 372–376, 395, 396
- proband, 32, 33, 41, 44, 46, 48, 51, 54, 167, 204, 218, 248, 368, 376, 381, 387, 394–396
- progeria, 180
- pro-inflammatory cytokine, 144, 339, 424
- prophase, 4–6
- protease-3, 190
- protein C, 270, 274–277
- protein C deficiency, 275, 276
- protein S deficiency, 275–277

- proteinase inhibitor (Pi), 189
- Proteome, 35
- prothrombin gene mutation (PTM), 275
- proto-oncogenes, oncogenes and carcinogenesis, 346, 352–354
- pseudoautosomal regions, 22
- PTEN mutations, 203
- public expectations, 80
- public health programs, 141
- pulmonary cysts, 203–205
- pulmonary surfactant, 195
- purine, 1, 2, 108
- pyrimidine, 1, 2, 104
- Pyruvate Kinase Deficiency (PKD), 261
- q arm, 3, 198, 328
- quality of life, 59, 60, 82, 105, 293, 307, 316, 348, 377, 384, 412, 423, 425, 428
- radiation therapy, 278, 300, 424
- random assortment, 6, 25
- RAPID approach, 35, 36, 50, 58, 60–62, 149, 370, 375, 394
- RAPID Approach and Cancer Genomics, 369–376
  - Utilization of RAPID for breast cancer, 394–395
- rare chromosomal anomalies, 167
- RBC osmotic fragility, 260
- rearrangements, 68, 69, 201, 203, 281, 282, 352, 374, 391
- recurrence risk, 19, 73, 392, 419
- red blood cell, 108, 216, 255
- religious background, 75
- renal tumors, 204, 205
- replication, 1–5, 15, 181, 211, 212, 215, 221, 278, 352, 354, 366, 378, 419
- reproductive outcomes, 123
- reproductive plan, 59, 125
- residual dried blood spots, 144–146
- Resources for Genetic/Genomic Neurological Disorders, 315–317
- Resources for Counseling & Testing, 79
- response to analgesics, 426
- retinoblastoma, 20, 200, 350, 354, 356
- retinoblastoma (RB1), 20, 200, 350, 354, 356
- Rett syndrome, 23
- rheumatoid arthritis, 153, 191, 331, 335
- ribonucleic acid (RNA), 10, 215, 295, 358
- ribosome, 13, 278
- Risk Assessment and Cancer Genomics 369–376
- Risk Assessment and Identifying individuals suspected
  - for Lynch Syndrome, 380
- risk communication, 31, 33, 35, 38, 60, 61, 87, 370, 375, 376, 396
- Risk Communication/Counseling and Risk Management, 375–376
- Risk Identification and Risk Elements, 372
- risk management, 33–36, 60, 61, 78, 365, 370, 375, 376, 377, 390, 396
- risk probability, 34, 35, 57, 58, 59, 62, 370–376
- ristocetin cofactor, 271, 273
- RNA polymerase, 12, 358
- Robertsonian translocation, 9, 10
- Rubinstein-Taybi syndrome, 155
- sapropterin dihydrochloride, 293
- schizophrenia, 27, 1270
- Schwachman-Diamond syndrome (SDS), 277, 278
- Schwannomas, 297–300, 364
- Secondary Prevention and enhanced Surveillance, 377
- second-tier test, 143
- segregation analysis, 241
- seizure disorder, 126
- sense strand, 10–12, 15–18
- sequenced, 144, 241, 418
- sequential screening, 72
- serum EPO, 261, 262
- Severe Combined Immunodeficiency (SCID), 142, 143, 146
- Severe congenital neutropenias (SCN), 279
- severe recurrent ear infections, 194
- sex chromosome aneuploidy, 130
- sex cord tumors with annular tubules (SCTAT), 386
- short interfering RNA (siRNA), 14
- short stature, 125, 129, 151, 153, 155, 157–161, 198, 277, 279, 298, 305, 331
- sickle cell anemia, 16, 48, 136, 143, 257, 259
- sickle cell disease (SCD), 19, 21, 42, 54, 125, 132, 135, 142, 146, 256, 257, 413
- sickle cell trait (SCT), 132, 257
- Sigma Theta Tau, 413
- signaling pathways, 203, 204, 352, 354, 356
- simultaneous sequencing, 70
- single nucleotide polymorphism (SNP), 27, 167, 211, 223, 332, 348, 391, 392
- single-gene disorders, 127, 189, 223, 225, 327
- situs inversus totalis, 194
- small cell lung cancer (SCLC), 190, 200–202
- smoking, 32, 43, 44, 100, 126, 134, 189, 191, 200, 202, 204, 210, 2, 218, 227, 262, 275, 307
- SNP arrays, 223, 227, 229
- social support, 73, 78, 80, 376
- somatic mosaicism, 21
- somatic mutation, 15, 20, 262, 280, 283, 351, 354, 362, 366
- Sotos, 161, 162
- Southern blot, 278, 286
- sperm motility, 194
- spermatogenesis, 126
- spherocytosis, 260, 278
- spina bifida, 26, 126



- spinal muscular atrophy (SMA), 71
- spindle fibers, 4, 6
- splenectomy, 260, 267
- splicing, 12, 13, 313
- spontaneous de novo mutation, 167, 297, 298
- spontaneous pneumothorax, 204, 364
- sporadic cancer, 346, 351, 356, 362, 369
- squamous cell cancer, 203
- start codon, 10, 11, 13
- State Boards of Nursing, 414
- statistical trend data incidence and mortality, 346–347
- stem cell theory, 349
- Stickler syndrome, 153
- stillbirth, 126, 129, 131, 132
- stop codon, 10–18, 258
- Storage Pool Deficiency (SPD), 272
- strategic management, 413, 414
- submetacentric, 3
- substance abuse, 44, 127, 424
- suicide, 61, 302
- Summer Genetics Institute (SGI), 410
- symptom management, 303, 412, 423, 428
- synthetic elastase inhibition therapy, 191
- Systemic mastocytosis (SM), 284
  
- T helper 2– (Th2–), 197, 200
- tachypnea, 194, 195
- tall stature, 151, 157–159, 161, 162
- Tamoxifen, 102, 374, 376, 393
- targeted mutation analysis, 69, 70, 72
- targeted physical examination, 52, 394, 411, 415
- Tay Sachs, 21, 71, 131, 136
- telomerase, 4
- telomere, 4, 181, 278,
- telophase, 4, 6
- thalassemia, 21, 136, 143, 159, 255–258, 264
- thiopurine methyltransferase (TPMT), 107
- Thiopurines, 107, 393
- third party payers, 414
- three-generation pedigree, 31, 37, 46, 47, 55, 59, 61, 62, 123, 124, 204, 414
- thrombocytopenia, 104, 268, 269–272, 274, 277–280
- thrombocytopenia and absent radii (TAR), 268
- thrombocytosis, 268, 271, 272, 283
- thrombophilia, 275–277
- thrombopoietin (TPO), 268
- thrombotic thrombocytopenic purpura [TTP], 270
- thymine, 2, 10, 12, 104
- Timothy (syndrome), 167
- tobacco, 42, 124, 191, 196, 198, 199, 361
- TP53, 199, 203, 282, 283, 389
- training, 34, 73, 100, 143, 375, 377, 395, 410–414
- transcriptomics, 209, 215, 222, 229, 250
- transcription, 2, 10–15, 20, 134, 180, 198, 214, 215, 289, 295, 301, 304, 311, 313, 328, 336, 338, 352, 354, 356, 358, 359, 366, 418, 424, 427
- transfer RNA (tRNA), 12, 13
- transferrin saturation, 263
- transgenerational epigenetics, 125
- translation, 2, 10–15, 28, 79, 145, 182, 289, 295, 297, 306, 313, 345, 358, 359, 391, 412, 420
- translocation, 8–10, 102, 131, 281, 282, 285, 331, 351–353, 391
- Treacher-Collins syndrome, 153
- triggers, 32, 185, 196, 198, 262, 336, 428
- trinucleotide repeat, 31, 57, 128, 293, 294, 301
- triplet, 10, 25, 128
- Tri-Service Nursing Research Program, 413
- trisomy, 8, 10, 136, 153, 155, 159, 161, 167, 173, 280
- trisomy 21 (DS), 155, 159, 161, 167, 280
- tuberculosis, 190, 195, 336
- tuberous sclerosis, 20, 28, 126, 167
- Tumor growth factor-beta (TGF- $\beta$ ), 192
- tumor markers, 360, 391
- tumor markers and breast cancer (*Example of*), 391–392
- tumor markers and colon cancer (*Example of*), 392
- tumor necrosis factor (TNF), 424
- tumor suppressor, 199, 200, 204, 297, 298, 3283, 36, 345, 352, 353–359, 362–366, 397, 419
- tumor suppressor genes, 352, 353–356
- Turcot syndrome, 380, 386
- Turkish, 133
- Turner syndrome, 8, 127, 129, 155, 157, 160, 161, 167
- twin studies, 195, 196, 210, 218, 426
- Type 1 Diabetes Mellitus (T1DM), 330
- Type 2 diabetes mellitus, 327, 331
- Type II pneumocytes, 195
- typical and atypical development, 166
  
- UDP-glucuronosyltransferase 1A1 (UGT1A1) and UGT1A1 genetic testing, 105, 106
- uninformative result, 70, 72, 77, 78
- uniparental disomy, 24, 331
- uracil, 10, 12, 99, 101, 103, 104, 106, 116, 393
- United States Food and Drug Administration (FDA), 72
- U.S. Secretary of Health and Human Services (HHS) Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), 142
- Usher syndrome, 303, 305, 317
  
- valproate, 126
- valproic acid (VPA), 126, 127, 259
- variable expression, 209, 295, 297
- variant of unknown/uncertain significance, 33, 70

- variants of Lynch Syndrome (Muir-Torre and Turcot), 380
- vascular dementia, 111, 179
- velocardiofacial syndrome (VCFS), 153
- venous thrombosis, 40, 224, 226, 269, 275, 276
- vertical transmission, 19, 33, 55, 56, 386
- vestibulocochlear nerve (tumor), 298
- virtue, 85–87, 90, 182
- vitamin B12, 127, 268
- Vitamin D deficiency, 157, 337
- Vitamin D3, 309, 337
- VKORC1 genotypes, 109, 110
- von Hippel-Lindau (VHL), 57, 262, 365
- von Recklinghausen disease, 153
- von Willebrand disease (VWD), 134, 269–271
  
- Warrdenburg syndrome, 265, 285
- Web Based Genetic Institute, 410
- Werner syndrome, 180
- WHIM syndrome, 265
- white blood cell, 255, 264, 265, 267
  
- whole exome sequencing, 33, 36, 241, 417
- wild type, 15–18, 106–112, 201, 281, 336, 366, 392
- Williams syndrome 155
- Wiskott-Aldrich syndrome, 268, 272
- Wolffian duct 130
- Wound healing 152, 243, 266, 414
- Whole genome sequencing, 33, 80, 87, 96, 115, 116, 241, 249, 389, 391, 414, 417
  
- X chromosome, 2, 18, 19, 21, 22, 33, 56, 128–130, 136, 159, 161, 168, 198, 242, 261, 273, 274, 296
- X-inactivation, 22
- X-linked dominant, 19, 23
- X-linked ichthyosis, 23
- X-linked inheritance, 33
  
- Y chromosome, 2, 19, 21, 22, 23, 126, 129
  
- zonulin pathway, 335
- zygotene, 5